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Abstract
Sepsis, a systemic inflammatory response to an infection, is a significant cause of
morbidity and mortality worldwide. The microcirculation during sepsis fails, in part, due
to microthrombosis and the resulting plugging of capillaries, precipitating organ failure.
Intravenous injection of ascorbate has been shown to reduce capillary plugging, however
the mechanism of this protective effect is unclear. We hypothesized that ascorbatemediated destabilization of the microthrombi through promoting fibrinolysis could
contribute to this protection.
We showed that streptokinase, a pro-fibrinolytic agent, reduced the capillary
plugging to a similar degree as ascorbate. This similarity provided the impetus for
studying the effect of ascorbate on fibrinolysis. Sepsis increased the urokinase
plasminogen activator (u-PA) and tissue plasminogen activator (t-PA) mRNA expression
in the skeletal muscle and liver in mice. No effect of ascorbate was observed on u-PA or
t-PA expression levels. Sepsis also increased the plasminogen activator inhibitor 1 (PAI1) mRNA and protein expression and activity in these tissues, but ascorbate did not affect
these increases.
The local PAI-1 release by both platelets and endothelial cells may play a critical role in
microthrombus formation in capillaries. We observed that PAI-1 released by isolated
endothelial cells was not affected by ascorbate. However, thrombin-induced PAI-1
release from platelets was inhibited by ascorbate pH-dependently. We have also
discovered that the PAI-1 release from platelets was nitric oxide independent.
It has been shown that PAI-1 has a protective role in sepsis, namely that PAI-1 knockout
leads to increased bacterial content, increased neutrophil apoptosis and increased
mortality. Therefore, the lack of effect of ascorbate on PAI-1 in the tissue may maintain
PAI-1’s beneficial role in sepsis. Consistently, we observed that sepsis-induced increases
in bacterial count, PAI-1 expression and myeloperoxidase content in various organs were
not affected by ascorbate.
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Overall, the lack of effect of ascorbate indicates that the protection by ascorbate through
reduced capillary plugging is not through a fibrinolytic mechanism. Other mechanisms
such as platelet-endothelial cell adhesion and changes in red blood cell deformability in
the capillaries should be explored as possible mechanisms of protection by ascorbate.

Keywords
Sepsis, ascorbate, capillary blood flow, plasminogen activator inhibitor-1, fibrinolysis
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Chapter 1
INTRODUCTION
This thesis examines the role of the fibrinolytic system on the reduction in capillary
perfusion observed during sepsis. To this end, this thesis focuses on the role of
plasminogen activator inhibitor 1 (PAI-1), an anti-fibrinolytic factor, in reduced capillary
perfusion during sepsis, and examines whether ascorbate (reduced vitamin C) restores
capillary perfusion and alters immune response in a PAI-1 dependent manner. This
introduction presents background information on: i) sepsis, and its contribution to
reduced capillary perfusion, ii) fibrinolysis, including the components of coagulation
leading to fibrin formation, and iii) ascorbate, including its beneficial effects in septic
patients and animals.

1.1 SEPSIS

1.1.1 Epidemiology and significance
Sepsis is a major cause of mortality worldwide, directly responsible for 1.4% of all deaths
(76) and implicated in between 6-10% of all deaths in Canada and the United States of
America each year (4, 106). Research on sepsis has not reduced the mortality rate, which
was reported to have increased by 0.67% per year between 1995 and 2005 (106). As
survival from sepsis is dependent on the availability of intensive care unit services, the
mortality rate is most likely higher in developing countries with limited medical facilities
(91). The mortality rate of septic patients in Canada, the United States of America and
European countries is between 20 and 47% (3, 66, 164).
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Sepsis is defined as a systemic inflammatory response to an infection (163). A
variety of criteria are used to confirm diagnosis of sepsis, including several scoring
systems that assess the severity of particular symptoms. Sepsis is difficult to diagnose as
there are a variety of symptoms that may be present in an individual patient. To make a
diagnosis of sepsis, a patient must have a suspected or confirmed infection along with
several of the following signs and symptoms: fever/hypothermia, tachypnea/respiratory
alkalosis, positive fluid balance/edema, general inflammatory reaction, altered white
blood cell count, increased levels of biomarkers (C-reactive protein, IL-6, procalcitonin),
arterial hypotension, tachycardia, increased cardiac output, low systemic vascular
resistance, high venous saturation O2, altered skin perfusion, decreased urine output,
hyperlactatemia (increased base deficit), signs of organ dysfunction, hypoxemia,
coagulation abnormalities, altered mental status, hyperglycemia, thrombocytopenia,
disseminated intravascular coagulation, altered liver function (hyperbilirubinemia), and
intolerance to feeding (altered gastrointestinal motility) (58). In general, increasing
numbers of symptoms indicate more severe sepsis, and a higher mortality (164).
In 2011, the only drug approved solely to treat sepsis, Drotrecogin alfa, was
withdrawn due to a lack of efficacy (126). As a result, currently the only treatment
option available to physicians is supportive in nature, focusing on maintaining blood
pressure and respiration while eliminating the bacterial infection, in the hope that the
inflammation will resolve on its own (49). Aside from the aforementioned Drotrecogin
alfa, treatments targeting the inflammation and coagulation have at times shown promise
(1, 108, 149) but were deemed to be either not effective or inconclusive in the treatment
of sepsis. Their use is either not recommended or used on a case by case basis as an
experimental treatment. Our lack of knowledge of the mechanisms involved in the septic
pathophysiology has limited the development of drugs and other treatment strategies.

1.1.2 Pathophysiology of sepsis
The inflammatory response during sepsis is perpetuated by the production of cytokines
intended to protect the host from the invading pathogens. Infections caused by gram-
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negative bacteria initiate sepsis through the lipopolysaccharide (LPS) present on the
bacterial wall. The LPS interacts with toll-like receptor 4 (TLR4), primarily located on
leukocytes and a key component of the innate immune system (135). The activation of
TLR4 causes the induction of a signaling cascade ultimately resulting in the production
of various pro-inflammatory cytokines such as tumor necrosis factor α (TNFα),
interleukin-1β (IL-1β) and interleukin-6 (IL-6), all of which are markedly increased in the
plasma of septic patients (51). In gram-positive bacterial infections, substances such as
lipoteichoic acid are secreted instead of LPS, activating TLR2 with similar production of
cytokines (150). Both TLRs signal through activation of NFκB (123). The LPS-induced
cytokine storm perpetuates the response by activating other components of the immune
system and further recruiting cells such as the neutrophils and macrophages to the site of
infection. In addition stimulation of endothelial cells and platelets occur. LPS and/or
cytokines increase the levels of pro-aggregation and adhesive proteins, reactive oxygen
species (ROS) and nitric oxide (NO) (123, 135). The changes brought about due to the
activation of the immune system, endothelial cells and platelets lead to many
pathophysiological alterations such as systemic hypotension, reduced capillary perfusion,
decreased ability to use the oxygen present, reduced resistance in the systemic
vasculature and reduced cell-to-cell signalling in the cells lining the vasculature (14, 32,
58, 77, 161-163). These alterations lead to increasing maldistributions of blood flow and
oxygen supply in the capillary bed, causing tissue damage and possible progression to
organ dysfunction and failure (58, 140).

1.1.3 Reduced capillary perfusion
As alluded to previously, a reduction in capillary perfusion in various tissues of
experimental animals and humans is a hallmark of sepsis (9, 13, 137). Reduced capillary
perfusion, defined as an increase in the number of capillaries with stopped flow, is
believed to contribute to organ dysfunction and failure due to the reduction in oxygen
delivery to the tissue (52, 158). Lower oxygen delivery to the tissues, due to reduced red
blood cells traveling through capillary beds lead to local tissue hypoxia and
mitochondrial dysfunction. Despite the resolution of septic shock in most patients,
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reduced capillary perfusion leading to organ failure was still linked to a third of total
patient deaths (131), while mortality increased as capillary perfusion decreased (156).
Recent studies suggest that the reduced capillary perfusion is due in part to platelet
adhesion and aggregation, and an increase in fibrin in the plugged capillaries (137).
However, when platelets were depleted, capillary perfusion did not fully recover (137),
indicating that the mechanism of capillary plugging is not exclusively due to platelet
adhesion and aggregation.
It is important to note that, in sepsis, reduced capillary perfusion is due to
plugging in capillaries themselves rather than plugging in the supplying arterioles or
draining venules. It has been observed that blood flow stops in capillaries even when
these arterioles and venules are perfused (137, 159). The presence of a precapillary
sphincter (i.e., smooth muscle cells surrounding the vessel immediately upstream of the
capillary) in skeletal muscle is debated. Studies have found no evidence of a precapillary
sphincter (37) or that the sphincter is present but not innervated (45), therefore
contraction of a precapillary sphincter as a normal physiological process cannot
adequately explain the lack of perfusion in select capillaries of the hind limb skeletal
muscle (this process cannot be excluded from some other skeletal muscle beds such as
the cremaster muscle (8)). The lack of an influence from a precapillary sphincter points
to the presence of a pathological process controlling the reduction in capillary perfusion
during sepsis.
There are several possible factors that may contribute to capillary plugging.
Leukocytes are large enough that should they adhere to the capillary wall they would
fully occlude the capillary vessel. There is merit in this, as leukocyte adhesion has been
reported to increase during sepsis or endotoxemia (73, 103). The relative contribution of
leukocyte adhesion in the reduction in skeletal muscle capillary perfusion is likely low as
very few leukocytes are observed in the septic skeletal muscle, instead being focused in
the liver and lungs (104, 144). It is for this reason that it was concluded that leukocytes
play little role in the capillary plugging in the septic rat skeletal muscle (125). Previous
work in our lab confirmed that capillary plugging in a septic mouse skeletal muscle is not
greatly influenced by leukocytes (137, 186). In addition to leukocytes, red blood cells
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could potentially contribute to capillary plugging due to their decreased deformability
during sepsis (9, 110). The role of red blood cell deformability in capillary plugging has
not been directly studied during sepsis. As the major components in microthrombi,
platelets and fibrin can be expected to play some role in capillary plugging during sepsis.
Indeed, both increased platelet activation and fibrin formation have been observed in
septic animals and humans (83, 137, 140). The formation of microthrombi in the
capillaries, mediated by platelet sticking to the endothelium and fibrin mesh formation,
would likely lead to the occlusion of at least some capillaries, blocking the flow of blood
through those particular capillaries. Platelet adhesion has been implicated in capillary
plugging (137, 138), however investigating the role fibrin and the mechanism of its
breakdown play in capillary plugging will be the focus of the present thesis.
During sepsis, fibrin breakdown decreases with increasing severity (61). This
would serve to increase the fibrin content in microthrombi, and combined with platelet
trapping in the capillary bed would increase the chance large enough microthrombi could
form to fully occlude the capillary flow. Evidence supporting this effect includes our
observation that capillaries typically go through a phase of intermittent flow prior to total
stoppage, suggesting that the dynamic process of building up and breaking down the
microthrombus slowly shifts from equilibrium to a progressively more pro–thrombotic
state, ultimately leading to a plugged capillary when microthrombus breakdown is
insufficient to maintain flow through the capillary (140).

1.1.4 Oxidant production in sepsis
The major endogenous ROS molecules are the free radicals superoxide, hydroxyl
and peroxynitrite. The effects of ROS are localized due to the inability of the radicals to
cross the cell membrane. Unlike the free radicals, hydrogen peroxide, a non-radical
substance, can freely diffuse across the cell membrane, and therefore spread damage
beyond the cell in which the ROS was intitally produced (127). All forms of endogenous
ROS are essential in cell signaling and the maintenance of the normal homeostatic state
in the body, and must be present in small quantities. Superoxide is converted by

6

superoxide dismutase, located throughout the body, into hydrogen peroxide. The
hydrogen peroxide is inactivated through further conversion into water through the
actions of catalase and glutathione peroxidase (34). Superoxide also readily reacts with
NO and forms peroxynitrite (127). Under pathological conditions of enhanced NO and
superoxide production, peroxynitrite can have detrimental effects on the nearby cells
through damage of proteins, lipids and DNA (54).
There are a number of systems that contribute to ROS, however the only enzymes
whose primary purpose is to produce superoxide are the NADPH oxidases found, for
example, in neutrophils, macrophages and endothelial cells (15, 127). It has been
demonstrated that LPS and various inflammatory cytokines stimulate NADPH oxidase,
increasing ROS production and thus making an important contribution to the
pathophysiological state in sepsis (87, 179, 184).
Septic patients are known to have both greatly increased levels of inflammatory
cytokines and reduced levels of the antioxidant ascorbate (28, 46, 63). Indeed, ROS has
been shown to have numerous effects during sepsis including inducing the coagulation
cascade (62), activating platelets (25, 120) and causing endothelial dysfunction (7). The
combination of increased ROS production due to inflammatory cytokine signaling and
reduced ascorbate levels likely result in enhanced oxidative stress (27). It has been
demonstrated that removal of the NADPH oxidase subunit gp91phox lessened the sepsis
induced reduction in capillary perfusion (159) and reduced platelet adhesion (137), while
treatment of mice or rats with ascorbate prevented or reversed the observed capillary
plugging (5, 159, 160).

1.1.5 Nitric oxide during sepsis
NO has several important functions in vivo, including acting as a vasodilator, as a
signaling molecule to maintain vascular homeostasis, and as an important component of
the immune response. NO has been demonstrated to inhibit platelet activation and
aggregation (56, 74) and leukocyte adhesion to the endothelium and platelets (55, 74),
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suggesting that local sources of NO may inhibit clot formation at the capillary level. The
endogenous source of NO is the three nitric oxide synthases (NOS), endothelial NOS
(eNOS), neuronal NOS (nNOS) and inducible NOS (iNOS). The production of NO is
facilitated by the NOS enzymes, where L-arginine is converted to L-citrulline in a two
step process involving NADPH, H+ and O2. NO synthesis occurs only in the presence of
the calcium dependent co-factor calmodulin, flavin adenine dinucleotide, flavin
mononucleotide, heme and tetrahydrobiopterin (BH4) (57). The co-factors facilitate the
movement of electrons from NADPH to heme, however if any step in this process is
interrupted (referred to as uncoupling), such as the consumption of one co-factor,
superoxide can be produced and released (42).
During sepsis there is increased NO production evidenced by the rise in nitrite
and nitrate levels in the blood plasma of both humans and animals (81, 146). The major
source of increased NO is the increase in expression of iNOS through signaling by LPS
and inflammatory cytokines such as TNFα (2). It has been demonstrated that the
increased NO production causes hypotension through arteriolar hyporeactivity and
inappropriate vasodilatation (122). Though iNOS is likely the major source of NO
production during sepsis, genetic knockout of this, or either of the other two NOS
isoforms (eNOS, nNOS) failed to improve the capillary perfusion, suggesting that the
capillary plugging is not related to the arteriolar hyporeactivity or vasodilation resulting
from excess NO production (159). In another study, the use of iNOS inhibitors did
improve the arteriolar blood pressure (16), suggesting that hypotension is not responsible
for the reduced capillary perfusion seen in sepsis. Ascorbate treatment does reduce
capillary plugging in septic mice independently of iNOS or nNOS (137). Interestingly,
the beneficial effect of ascorbate is eliminated in eNOS-/- mice, suggesting that ascorbate
functions through an eNOS dependent pathway. The eNOS isoform is found primarily in
the endothelial cells, while other cells such as platelets, erythrocytes and smooth muscle
cells also express it (20, 53, 152). The primary role of the NO produced by eNOS is to
maintain vascular homeostasis through the regulation of vascular tone and preventing
platelet aggregation, apoptosis and smooth muscle cell proliferation (22, 43, 48, 154).
During various disease states including sepsis, the supply of BH4 can become depleted,
leading to the uncoupling of the NOS (42). Due to the uncoupling, superoxide is
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produced and released by the NOS enzymes, further contributing to the ROS in the
vasculature. Additional peroxynitrite production due to impaired eNOS function is
believed to cause further damage, particularly in the capillaries, leading to capillary
plugging through activation of coagulation (159).

1.1.6 Bacteria and the immune response during sepsis
Though not essential to the development of the inflammatory response, a bacterial
infection is most often present in patients presenting with sepsis. Other less common
sources of infection are fungi, viruses and parasites. There are a multitude of bacterial
infections that can lead to sepsis, with the most common sites of infection being the
lungs, abdominal cavity and urinary tract (49). An infection of the abdominal cavity
commonly results in peritonitis, an inflammation of the peritoneum lining the peritoneal
cavity. Peritonitis can be caused by a ruptured appendix, perforation in the digestive tract
or bacteria otherwise entering the peritoneal cavity (100, 124). Many bacteria are
typically present in the digestive tract, including both gram-negative and gram-positive
species. It has been determined that stool samples from the cecum of mice contain
approximately 40 different species of bacteria, with Escherichia coli, Enterococcus and
Staphylococcus strains dominating the aerobic bacteria content (147, 171). Peritonitis
occurs as a result of the presence of some or all of these bacteria, with the anaerobic
bacteria likely playing the greatest role due to the anaerobic nature of the peritoneum
(124).
The immune response to a bacterial infection begins with the activation of pattern
recognition receptors by pathogen-associated molecular patterns present on bacteria (and
other pathogens) and damage-associated molecular patterns released in response to cell
damage caused by pathogens (50, 58, 169, 174). There are four main classes of pattern
recognition receptors in animals: the TLRs, C-type lectin receptors (CLR), NOD-like
receptors (NLR) and RIG-I-like receptors (RLR) (58, 169). In addition, there are a
number of secreted pattern recognition receptors, such as C-reactive protein and lectins
that are present in the blood and bind to invading pathogens to alert immune cells of the
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presence of these pathogens (114). The pattern recognition receptors activate the innate
immune system, leading to inflammation and activation of the complement system (174).
Inflammation, caused in part by various cytokines, increases blood flow to the infected
tissue, leading to increased temperature, swelling and recruitment of leukocytes in an
effort to kill the pathogen. Typically, the first leukocytes arriving to a site of bacterial
infection are the neutrophils, which phagocytose the invading bacteria, killing them with
a respiratory burst involving the NADPH oxidase production of superoxide along with
proteins released through degranulation, such as myeloperoxidase (139, 173).
Macrophages arrive at the site of infection at the same time as neutrophils and also play a
role by removing dead or dying cells, phagocytosing bacteria missed by the neutrophils,
and producing inflammatory cytokines (24, 60). The complement system, a cascade of
proteins circulating in the blood, is the other component of the innate immune system.
The inactive precursor complement proteins are activated by several different pattern
recognition receptors, including C-reactive protein and mannose-binding lectin (19, 47).
The complement system works by attracting neutrophils and macrophages, along with
increasing vascular permeability and opsonizing bacteria (coating the bacteria increases
phagocytosis) to weaken and destroy them (19, 128).
In cases of bacterial sepsis, it is believed that the immune response begins
normally, with neutrophil recruitment and complement activation. For some reason that
has yet to be determined, the inflammatory response becomes aberrant and spreads to the
entire body (58, 174). The increase in inflammation leads to the activation of the
coagulation system, further production of ROS and a decrease in fibrinolysis (140) (see
sections 1.2 and 1.3 for further discussion of coagulation and fibrinolysis). The
prolonged inflammatory state directly or indirectly leads to many of the detrimental
effects commonly seen in sepsis, including fever, hypotension and organ dysfunction and
failure. Though the bacterial infection is the initial trigger, often the inflammatory
response actually causes more damage than the infection itself. It is for this reason that
antibiotics alone are often insufficient to treat sepsis (112).
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1.1.7 Models of sepsis
There are a number of models that have been used previously to study sepsis in a variety
of different species. Most studies, largely due to cost, are conducted in mice, though rats,
rabbits, pigs, sheep and non-human primates such as baboons have been used in a variety
of septic models (40, 168). The models have been developed to attempt to best mimic the
pathology observed in septic patients. Most septic models are based on one of two basic
pathogenic mechanisms: endotoxemia using a variety of inflammatory cytokines, and
bacterial introduction through three main routes: direct injection of bacterial colonies into
a host, cecal ligation and puncture (CLP), where the intestinal wall is compromised
resulting in peritonitis, and fecal injection into peritoneum (FIP), where peritonitis is
caused by administration of feces directly into the peritoneum.

1.2 COAGULATION

1.2.1 Overview
Coagulation is the development of clots from blood. Under physiological conditions,
coagulation is essential for the maintenance of vascular homeostasis. Initiation of
coagulation begins with platelet activation and adhesion (see section 1.2.4), followed by
strengthening of the developing clot with fibrin (see section 1.2.2). Clot development
and breakdown (fibrinolysis, see section 1.3) is a dynamic process that is tightly
regulated under normal physiological conditions (89). Dysfunction in this regulation,
whether through hypercoagulation (excessive coagulation) or hypocoagulation
(insufficient coagulation) has been shown to result in various pathological disease states
(89, 101, 140).
Coagulation is initiated through two separate pathways: the contact activation
pathway and the tissue factor (TF) pathway, both ultimately leading to a common
pathway. The contact activation pathway, or intrinsic pathway, is activated when
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exposed collagen comes in contact with factor XII activating it to factor XIIa and
beginning a cascade of activation first of factor XI to XIa, then factor IX to IXa and
activation of factor X to Xa. Under normal conditions, the endothelial cells form a
barrier between the blood and collagen. In addition to the contact activation pathway,
platelets are directly activated when exposed to collagen and begin to adhere to the
exposed site. The TF pathway, or extrinsic pathway (illustrated in Figure 1.1a), is
activated when blood comes in contact with TF produced mainly by cells not normally in
contact with the blood. This activates factor VII to VIIa, which then directly activates
factor X to Xa. Activated factor Xa initiates the common pathway for both coagulation
pathways, with the conversion of prothrombin into the active protein thrombin.
Thrombin then converts fibrinogen into fibrin, leading to the formation of a fibrin mesh
in the developing clot. Thrombin also further activates platelets and endothelial cells (30)
and causes a positive feedback activating factor VII to VIIa, therefore increasing the
production of thrombin further (89). Under physiological conditions, most TF is
produced by vascular cells not in direct contact with the blood, however during
pathological conditions, upon stimulation by inflammatory cytokines, endothelial cells
and white blood cells have been shown to release TF (35).
It is common in septic patients to observe a wide variety of disorders in the
coagulatory system, including disseminated intravascular coagulation (DIC, consumption
of coagulation proteins in the microvasculature, ultimately resulting in consumption of
coagulatory factors leading to an inability to form clots), while thrombocytopenia (a
reduction in platelet count) can occur alone or in conjunction with DIC (84, 140). It has
been shown that there is extensive cross-talk between the inflammatory and coagulation
proteins, with many inflammatory cytokines activating the coagulation system. LPS
itself has been shown to increase the production of TF (148), while cytokines such as
TNFα have also been demonstrated to upregulate TF (11). As LPS itself induces the
production of TNFα, this would have a positive feedback in generating even more TF and
enhancing thrombin production. Inflammation has also been observed to alter
coagulation through a reduction in the levels of anti-coagulation proteins protein C (an
enzymatic inactivator of factors Va and VIIIa), tissue factor pathway inhibitor (an
inhibitor of thrombin as well as factor Xa, and ultimately inhibits the factor VIIa-TF
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Figure 1.1. Schematic of the coagulation (Panel A) and fibrinolytic (Panel B)
pathways during sepsis. Panel A: The coagulation system is initiated in sepsis by the
activation of TLR4 by LPS. This generates ROS, TF and cytokines that begin the
coagulation cascade. Coagulation occurs when the platelets become activated and fibrin
is formed, together composing the thrombus. As ascorbate acts as an antioxidant (see
section 1.4), I propose that ascorbate reduces the ROS and thereby inhibiting the
activation of the coagulation cascade. Panel B: I propose that activation of TLR4 also
initiates production of PAI-1, which then inhibits t-PA and u-PA (see section 1.3). This
leads to lower plasmin production and impaired fibrin degradation. Upon ascorbate
treatment, PAI-1 expression is reduced restoring plasmin production and fibrin
degradation. Activation of factors is indicated by arrows, inhibition is indicated by a T
line and reduced production during sepsis is indicated by an X.
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complex in conjunction with factor Xa), and antithrombin (an inhibitor of thrombin) (84,
89). In addition to enhancing coagulation, the breakdown of fibrin through the
fibrinolytic pathway can also be inhibited by inflammation (see section 1.3) (140).

1.2.2 Fibrin
Fibrin is a fibrous protein formed from its precursor fibrinogen during the blood clotting
process. It forms a polymerized mesh giving the blood clot strength and stability.
Besides the role in clot formation and support, fibrin is also involved in signal
transduction, eliciting cellular responses critical to normal cellular function (44, 178).
Fibrin is formed when thrombin cleaves the N-terminus of the fibrinogen α and β
subunits. This allows the cleaved ends to polymerize end to end with other fibrin
molecules (170). It is the cross-linking of fibrin molecules into a mesh that ensures the
structural integrity and three dimensional nature of the clot (172).
During sepsis, fibrin content is markedly increased due to increased TF mediated
thrombin generation (84, 89). In addition, fibrin degradation (fibrinolysis, see section
1.3) is reduced during sepsis (140), suggesting that both increased fibrin production and
stability contribute to the pathological clot formation during sepsis.

1.2.3 Endothelial cells
The endothelial cells that line the blood vessel walls are essential for vascular function by
forming a barrier between the surrounding cells and the vascular lumen as well as
facilitating critical components of the coagulation and inflammatory processes.
Endothelial cells produce and express several important adhesion proteins including Pselectin and von Willebrand factor (vWF) as well as the anti-fibrinolytic factor PAI-1
(96, 142). Upon activation, the Weibel-Palade bodies that contain the P-selectin and
vWF are expressed at the cell surface, facilitating the capture of platelets and coagulation
proteins. The secretion of PAI-1 by endothelial cells serves to stabilize the clots through
its anti-fibrinolytic activity. It has been demonstrated that endothelial cells can be
activated by numerous molecules, proteins and cytokines including LPS, thrombin, and
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TNFα (39, 59, 145). Endothelial cells can be damaged during sepsis, resulting in a loss
of the normal barrier function, allowing for increased vascular permeability and exposure
of the basement membrane and surrounding cells to the vascular lumen (64). The
resulting loss of barrier function can result in activation of coagulation and edema (82).

1.2.4 Platelets
Platelets are small anucleated cells derived from the fragmentation of precursor
megakaryocytes. They are small in size, their diameter ranging between 1-3 microns.
Platelets are essential to maintaining normal vascular homeostasis, primarily through a
contribution to the formation of clots. When activated, platelets aggregate and adhere to
adhesion molecules expressed on other cells, forming and strengthening the clots. In
addition to clot formation, platelets also play an essential role in the repair and
regeneration of connective tissues and other damaged tissues surrounding the vasculature
(117). Pathological disorders may result in altered platelet numbers or function. Low
platelet count (thrombocytopenia), or reduction in function (thrombasthenia), result in
excessive bleeding, while high platelet count (thrombocytosis) leads to pathological
clotting (141).
Activation of platelets occurs through exposure to a number of substances,
including thrombin, vWF, collagen, adenosine diphosphate, and thromboxane A2
produced by other platelets (88, 116). Upon activation, platelets change shape becoming
more spherical allowing for enhanced adhesion through increased platelet rolling (105).
Activated platelets also secrete three types of granules: dense, lambda and alpha. The
dense granules release molecules essential for the coagulation response (116). Alpha
granules release the pro-coagulation proteins including P-selectin, vWF, fibrinogen, and
the anti-fibrinolytic protein PAI-1 along with other proteins (88). The molecules secreted
from these granules serve as positive feedback to activate platelets as well as other
components of the coagulation and anti-fibrinolytic pathways (88, 116).

15

Thrombocytopenia is common in septic patients (10, 65), though the exact
reasons for the reduction in platelet count remain unresolved. It is known that activation
of coagulation does occur during sepsis, including platelet activation. The increased
release of thrombin, adenosine diphosphate, and thromboxane A2 (along with other
substances) during sepsis activates platelets leading to increased adhesion to the
vasculature and increased platelet aggregation (23, 70, 75, 84, 85, 99, 134, 140). In
addition, LPS and inflammatory cytokines have been shown to activate platelets (26, 119,
185), resulting in an increase in TF (130, 134). ROS has also been demonstrated to
increase platelet aggregation (21, 29, 166), while activated platelets have been shown to
release ROS (132, 166).

1.3 FIBRINOLYSIS

1.3.1 Overview
Fibrinolysis is the process by which fibrin is broken down, leading to the dissolution of
blood clots. Under normal physiological conditions, fibrinolysis removes clots that are
no longer needed, as well as regulating the size of clots so they do not become too large.
Fibrinolysis is initiated by the activation of plasmin from its precursor plasminogen (see
Figure 1.1B). Plasmin cleaves fibrin into degradation products, dissolving the fibrin
mesh and allowing for the dispersal of the clot. Abnormal fibrinolysis, either through
inhibition or over activation, has been associated with pathological disease states (67,
102).
Fibrinolysis is inhibited by two separate means, namely inhibiting plasmin
production, and directly inhibiting plasmin. Plasmin production is inhibited by the
plasminogen activator inhibitors, while α2-antiplasmin is the primary molecule
responsible for inactivating plasmin (67, 133). A disease process targeting either
pathway could alter fibrinolysis, either through the stabilizing effect of preserving fibrin,
or the anti-coagulation effect of uncontrolled fibrin degradation (86, 93, 167).
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1.3.2 Plasmin
Plasmin becomes an active enzyme upon cleavage from the inactive zymogen
plasminogen. Plasminogen is produced in the liver, circulates in the blood and is
incorporated into clots. Two activators of plasminogen, tissue plasminogen activator (tPA) and urokinase plasminogen activator (u-PA), cleave the molecule into plasmin when
plasminogen is bound to a clot or cell surface (90, 107). Active plasmin cleaves fibrin
and vWF along with several other pro-coagulation proteins into inactive degradation
products, such as D-dimers in the case of fibrin (90, 143). Both t-PA and u-PA are
produced by a wide variety of cells, and interact with plasminogen, fibrin and in the case
of u-PA, the u-PA receptor, to produce plasmin (90, 94). Plasmin is permanently
inactivated by α2-antiplasmin, halting the degradation of fibrin (80). Diseases that cause
pathological increases in the expression of t-PA or u-PA lead to hyperfibrinolysis and a
lack of clot stability and longevity (36, 118), whereas decreases lead to unchecked
clotting (33, 86). Decreased α2-antiplasmin under various disease conditions results in
an inability to maintain clots due to enhanced fibrinolysis. Increased α2-antiplasmin has
not been reported to occur (18, 71).
During sepsis, both t-PA and u-PA have been reported to have increased
expression, however this increase is likely counteracted by increases in the inhibitory
plasminogen activator inhibitors (129). Plasmin-antiplasmin complexes are increased
during sepsis, supporting the notion that plasmin production is increased during sepsis,
however increased plasmin may be offset by increased anti-fibrinolytic activity (86, 93,
102, 157).

1.3.3 Inhibition of plasmin
The production of plasmin is regulated by a dynamic balance between the plasminogen
activators (t-PA and u-PA) and their inhibitors PAI-1 and plasminogen activator inhibitor
2 (PAI-2). PAI-1 is the primary inhibitor of the activation of plasmin, acting through the
irreversible inhibition of both t-PA and u-PA (31). PAI-1 is produced by a variety of cell
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types, however in regards to intravascular clotting, the primary source is endothelial cells
(94). Inhibition of t-PA and u-PA eliminates the activation of plasmin therefore
stabilizing clots. Active PAI-1, the only form of PAI-1 with a known biological action, is
extremely unstable and spontaneously inactivates to a latent form unless stabilized by
vitronectin (17). The other known plasminogen activator inhibitor is PAI-2, however this
inhibitor is not generally detectable in non-pregnant patients, and has been reported to be
no more than five percent of the overall inhibitor content in the body (129). Pathological
changes in the production of PAI-1 have been reported, with depressed levels leading to
reduced ability to clot, and increased PAI-1 results in an inability to break down fibrin,
possibly leading to the formation of fibrosis, which can ultimately lead to organ damage
if allowed to occur over the long term (68, 69, 98, 115).
PAI-1 has been demonstrated to be increased during sepsis, while some reports
have observed an increase in PAI-2 as well (93, 95, 102, 129, 182). Overall, this leads to
an increase in anti-fibrinolysis, where less plasmin is produced. It is unclear whether this
increase just counteracts the observed increase in t-PA and u-PA or whether the increased
PAI-1 creates an even greater anti-fibrinolytic state (86, 94).
In addition to its fibrinolytic effects, PAI-1 has been demonstrated to play a role
in angiogenesis, macrophage migration and neutrophil efferocytosis (17, 79, 121). It is
interesting to note that all of these activities are related to wound healing and, as such,
PAI-1 clearly plays an essential role in this process. In addition, increasing evidence
points to a role of PAI-1 in obesity and cancer, where aberrant expression promotes
vascularization and therefore tumor growth (17).
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1.4 ASCORBATE

1.4.1 Overview
Ascorbate (a reduced form of vitamin C) is a water soluble antioxidant available extraand intra-cellularly in the body. Its primary function is to react with ROS (superoxide,
hydroxyl and peroxynitrite radicals), neutralizing the harm these radicals can cause.
Upon reaction between ascorbate and a free radical, ascorbate loses its reactivity and can
convert to dehydroascorbic acid (175). Ascorbate also plays a critical role in the
recycling of the antioxidant α-tocopherol (vitamin E) (155).
In humans, ascorbate is an essential vitamin obtained from diet, as the ability to
produce ascorbate has been lost. In contrast, most rodents produce their own supply of
ascorbate. During sepsis, blood plasma levels of ascorbate are markedly reduced (e.g.,
from 60 to 10 µM) in both patients and animals regardless of the ability to produce
ascorbate (5, 46). Indeed, there has been a report of a critically ill patient developing
scurvy (vitamin C deficiency) due to depletion of ascorbate in the blood plasma (63). It
is believed that impairment of the mechanisms of ascorbate recycling occurs during
sepsis (12). There is increased consumption of ascorbate in septic patients in order to
neutralize the increased ROS levels (12, 92, 175-177). Decreased plasma ascorbate
levels have been linked with decreased survival and more severe illness in septic patients
(46, 54, 177).

1.4.2 Treatment with ascorbate
Ascorbate, administered with vitamin E has been demonstrated to reduce organ failure,
shorten recovery time, and improve survival in critically ill patients (28, 113). Ascorbate
has also been shown to reduce mortality in burn victims and restore depleted plasma
levels in septic patients when given at high doses of greater than 1g per day (12, 92, 151).
In addition, the antioxidant succinobucol has been shown to reduce TF expression in LPS
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stimulated endotoxemia (97), thereby reducing coagulation and suggesting that sepsis
derived ROS plays a role in the initiation of coagulation.
Ascorbate given as an intravenous bolus has been demonstrated to enhance
capillary perfusion and responsiveness in the arterioles, improve the function of the liver,
reverse hypotension and decrease mortality in rodent models of sepsis (5, 137, 159, 160,
180, 181). Ascorbate reduced capillary plugging (137), and platelet activation and
aggregation in septic models (138). Capillary plugging has been demonstrated to
improve with ascorbate treatment when given with the onset of sepsis (5), as well as six
hours into sepsis, at a time when approximately 40% of capillaries were non-perfused
(137, 159, 160). The administration of ascorbate restored perfusion to approximately half
of the previously non-perfused capillaries (137, 159, 160). The improvement in capillary
perfusion in mice with ascorbate treatment is consistent in both a cecal ligation and
perforation (CLP) model (180) and a fecal injection into peritoneum (FIP) model (159).

1.4.3 Effects of ascorbate
As ascorbate acts as an antioxidant, it is likely that its protective effects would be at least
partly due to its ability to scavenge ROS in septic patients. Indeed, it has been
determined that removal of the gp91phox subunit of NADPH oxidase, eliminating the
NADPH oxidase ROS contribution, reduces capillary plugging, and that ascorbate
improves capillary perfusion to a similar degree (137). In addition, the protective effect
of ascorbate is eNOS dependent, likely through eNOS derived NO production, as the
addition of endogenous NO or tetrahydrobiopterin (BH4), an eNOS cofactor, both
improved capillary perfusion (159). The use of BH4 or ascorbate on eNOS-/- mice was
ineffective in reversing the capillary plugging (137, 159). As BH4 is oxidized by ROS,
which then uncouples from eNOS, increased ROS during sepsis ultimately leads to the
production of superoxide rather than NO, causing cellular damage through the production
of peroxynitrite (41, 78, 136). Ascorbate is known to be rapidly and readily taken up by
endothelial cells (175, 176). The antioxidant activity of ascorbate likely prevents the
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oxidation of BH4, resulting in a state of normal coupling of eNOS and resulting in
restored NO production (177).
NO prevents platelet activation and aggregation, and is one of the mechanisms
whereby NO maintains normal vascular homeostasis. One way NO prevents platelet
activation is through a reduction in the expression of the adhesion protein P-selectin on
both platelets and endothelial cells, though iNOS derived NO actually increases Pselectin expression (6, 56, 183). Reduced P-selectin decreases platelet-endothelial
adhesion and thrombus size (38, 56, 153), while ascorbate has been shown to reduce Pselectin expression (138). It must be noted that as PAI-1 is co-localized in the α-granules
in platelets, it is possible that a reduction of P-selectin expression may also indicate
reduced PAI-1 release, increasing fibrinolysis at the capillary level (88). Interestingly,
ascorbate was able to reduce P-selectin surface expression on platelets in a NO
independent manner (138), suggesting that α-granule secretion may be controlled by both
NO and another mechanism unrelated to its antioxidant properties.
Recently, it has been determined that ascorbate reduces neutrophil extracellular
trap formation, resulting in reduced cellular damage from excessive neutrophil activation
(109). There is ample evidence that ascorbate affects numerous aspects of the
inflammatory and coagulation systems, however the potential protective effects on the
fibrinolytic system remain to be determined.

1.5 RATIONALE, HYPOTHESIS AND OBJECTIVES

1.5.1 Rationale
Extensive research on sepsis has been conducted, yet no effective pharmacological
treatment targeting the inflammation has been developed. The failure of several
experimental treatments at the clinical trial stage reflects the lack of understanding of the
pathophysiology of sepsis at the molecular and cellular level. It has been demonstrated
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that capillary perfusion is reduced during sepsis, with poorer prognosis with increasing
microvascular dysfunction (5, 77, 131). It has been demonstrated that increased platelet
adhesion occurs in the skeletal muscle capillaries during sepsis, and that depletion of
platelets improves the capillary perfusion (137). In addition, studies have shown
increased fibrin deposition and a decrease in fibrinolysis during sepsis (84, 140).
However, complete removal of platelets, fibrin or the anti-fibrinolytic factor PAI-1 result
in decreased capillary perfusion or markedly reduced survival (72, 111, 137). The poor
prognosis through removing these critical components of coagulation highlights the
complexity of this process and our lack of understanding of the mechanisms involved.
The presence of both platelets and fibrin in capillaries shows that the capillary plugging is
caused by a physical blockage due to clot formation (137). To date, the role fibrinolysis
plays as it directly relates to capillary plugging has yet to be explored.
It has been many years since ascorbate treatment was shown to have beneficial
effects during sepsis, with a link becoming apparent as early as 1990 (165). In the years
since, it has been determined that ascorbate improves the capillary plugging (5), survival
(159), and most recently decreases platelet adhesion (137, 138). Despite these studies,
the mechanisms by which ascorbate facilitates these beneficial effects remains largely
undetermined. Ascorbate acts as an antioxidant, and its beneficial effects in reducing
capillary plugging is eNOS dependent in vivo, likely through the NO produced by eNOS
(137). However, it must be noted that ascorbate also has an effect on platelet adhesion
that is NO independent (138). This discrepancy suggests at least two separate
mechanisms play a role in the protective effect of ascorbate. As platelet depletion does
not restore capillary perfusion to the same extent as ascorbate (137), clearly ascorbate has
an effect on other systems in sepsis. As fibrin and adherent platelets were both located in
the non-perfused septic microvasculature (137), removal of fibrin through increased
fibrinolysis may enhance the capillary perfusion in conjunction with reduced platelet
adhesion. Exploration of the fibrinolytic state during sepsis will further elucidate the
mechanism of ascorbates protective effect as well as support the use of ascorbate as an
effective adjuvant therapy for sepsis.
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1.5.2 Hypotheses
1) Increased fibrinolysis results in reduced capillary plugging during sepsis.
2) PAI-1 expression in a septic mouse model is increased, leading to decreased
fibrinolysis.
3) Ascorbate promotes fibrinolysis in the skeletal muscle through a decrease in PAI-1
expression, restoring capillary perfusion during sepsis.

1.5.3 Objectives
1) Determine the effect of increased fibrinolysis on capillary perfusion in sepsis, and test
whether sepsis and ascorbate can alter the levels of pro- and anti-fibrinolytic factor
mRNA and protein expressions in an in vivo model of sepsis. This objective will be
addressed in Chapters 2 and 3.
2) Determine the effect of ascorbate on bacterial levels and the immune response in septic
organs. This objective will be addressed in Chapter 3.
3) Develop an ex vivo/in vitro model of sepsis to determine the effect of ascorbate on
sepsis-induced PAI-1 expression and release from platelets and endothelial cells. This
objective will be addressed in Chapter 4.
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Chapter 2

Effect of ascorbate on fibrinolytic factors in septic mouse
skeletal muscle

A version of this chapter has been accepted for publication in Blood Coagulation and
Fibrinolysis
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2.1 INTRODUCTION

Sepsis, the systemic inflammatory response to a local infection, leads to reduced capillary
bed perfusion and subsequent organ failure (33). Reduced perfusion of the
microvasculature in tissues correlates with organ failure and mortality during sepsis (24).
Using intravital microscopy, we have demonstrated that this reduction in
microcirculatory flow is due to a significant increase in the number of stopped-flow, or
plugged, capillaries (25, 30). The sepsis-induced coagulation of the microcirculation
involves platelet activation and adhesion, fibrin deposition, and both the formation and
strengthening of micro-thrombi (11). Furthermore, the opposing process of fibrinolysis
(breakdown of fibrin) is reduced in blood during sepsis (8). Subsequently, the microthrombi within the microvasculature are an important contributor to the blood flow
impairment in sepsis. The fibrinolytic process involves the pro-fibrinolytic t-PA and uPA, and the anti-fibrinolytic PAI-1, which inhibits t-PA and u-PA (29).
We also demonstrated in a mouse model of sepsis that an intravenous injection of the
antioxidant ascorbate at 6 h of sepsis (i.e., time when capillary plugging is prevalent)
restores capillary blood flow at 7 - 18 h of sepsis (30). Since ascorbate does not affect
arterial pressure post-injection (30), a local mechanism within the microvasculature could
be responsible for the restoration of capillary blood flow. Numerous local mechanisms
could explain this effect (4, 36), including the possibility that ascorbate enhances
fibrinolysis in septic capillaries, and thus restores blood flow. To this end, oxidative
stress has been shown to increase both mRNA and protein expression of t-PA, u-PA and
PAI-1 in endothelial cells (20).
To our knowledge, the effect of ascorbate on the fibrinolytic process in the septic
microvasculature has not been examined. The objective of the present study was to
determine the effect of sepsis and ascorbate on t-PA, u-PA and PAI-1 mRNA and protein
levels in the mouse model of sepsis. We hypothesized here that ascorbate restores blood
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flow in septic capillaries by stimulating local fibrinolysis via increasing t-PA and u-PA
and/or by inhibiting PAI-1 levels within the septic microvasculature.

2.2 METHODS

2.2.1 Animal preparation
All experimental protocols were approved by the University of Western Ontario Council
on Animal Care. Male wild type C57BL/6 mice (weight: 18-25 g, age: 1.5-4 months)
were obtained from the Jackson Laboratory (Bar Harbor, ME) and bred in our animal
facility. Sepsis was induced by fecal injection into peritoneum (FIP) as detailed
previously (25, 30). Briefly, feces was collected from the cecum of a minimum of two
donor mice for each experiment, suspended in sterile saline at a concentration of 75 mg
of feces/mL and stored overnight at 4°C. The following day, mice were anesthetized with
ketamine (80 mg/kg) and xylazine (4 mg/kg) prior to being injected intraperitoneally with
50 mL/kg of the feces solution. For our control sham mice, we substituted sterile saline
for the feces solution. All mice were given a subcutaneous injection of 1 mL of sterile
saline containing the analgesic buprenorphine (4 µg/mL) 30 minutes prior to FIP.
At 5 - 6 h post-FIP, the mice were anesthetized with ketamine and xylazine and kept
anesthetized with supplemental ketamine/xylazine doses for the remainder of the
experiment (1.5 h). The extensor digitorum longus (EDL) muscle was surgically exposed
and its surface was epi-illuminated and imaged using intravital microscopy as previously
detailed by us (25, 30). The EDL muscle was chosen because it is a suitable organ for
intravital microscopic examination of blood flow in the capillary bed. Other organs
present difficulty with this examination due to the breathing movement of the animal and
due to extensive surgery required to expose the capillary bed. It has been demonstrated
that the EDL capillary perfusion during sepsis shows the same fundamental features (e.g.,
blood flow stoppage during sepsis) as the liver, kidney, skin, sublingual surface, heart,
lung and brain (1, 24). We have used the EDL as a surrogate organ of the sepsis-induced
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capillary derangement in the other organs. Briefly, we used an upright microscope and
video-recorded 5 random fields (0.61 x 0.87 mm) per muscle. In each field we drew a test
line perpendicular to muscle fibers and counted capillaries perfused with red blood cells
and capillaries with stationary red blood cells (i.e., stopped-flow capillaries) crossing this
test line. We computed the percentage of stopped-flow capillaries from the total (perfused
+ stopped) and averaged the percentages from 5 fields. We used the intravital recordings
to verify that sepsis impaired capillary blood flow at 5 - 6 h post-FIP and to compute the
percentage of stopped-flow capillaries at 7 h (25, 30). At 5 or 6 h, we injected an
intravenous bolus (0.1 mL) of streptokinase (Sigma-Aldrich, Oakville, ON, 25000 U/kg),
ascorbate (Sigma-Aldrich, 10 mg/kg) (both dissolved in sterile saline), or saline. The
ascorbate dose is clinically relevant, as intravenous doses of the order of 1 g/day have
been given to critically ill patients (12). To examine the effect of ascorbate on
fibrinolytic factors in skeletal muscle, we harvested this tissue at 7 h for mRNA and
protein analyses of these factors. We also harvested the liver at 7 h, because the liver
could be a major source of fibrinolytic factors (22), which could be released into the
bloodstream and thus indirectly affect the microcirculation in the skeletal muscle.
Alternatively, we isolated microvascular endothelial cells from the skeletal muscle at 7 h
by excising, mincing and digesting the muscle in a collagenase enzyme solution and by
subjecting it to immunoseparation using lectin-coated magnetic beads as detailed
previously (2, 15). The purity of the endothelial cell isolates were not confirmed due to
limited cell availability, however we previously confirmed this method yields high purity
through vWF expression (2, 15). To assess the plasma level of the fibrinolytic factors,
we punctured the carotid artery to collect a systemic blood sample in sodium citrate.
Finally, we also collected blood in heparin for platelet count and thrombelastography.

2.2.2 mRNA expression
To extract mRNA, we used Trizol (Invitrogen, Burlington, ON) according to the
manufacturer’s directions. We treated the mRNA with DNAse I (Sigma-Aldrich)
followed by reverse transcription using Superscript II reverse transcriptase (Invitrogen).
We used qPCR to determine the mRNA expression levels of t-PA (primers: forward 5’-
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CTGAGGTCACAGTCCAAGCAATGT-3’ and reverse 5’GCTCACGAAGATGATGGTGTAAAGA-3’), u-PA (primers: forward 5’GCCGCTATCCTACAGAGCAC-3’ and reverse 5’-CAAGGGTATTGTTCCCCTCA3’) and PAI-1 (primers: forward 5’-GACAGCACTGTCAGGGTCCATAG-3’ and
reverse 5’-GCGGTCCTCCTTCACAAAGCTC-3’) in the skeletal muscle, liver and
endothelial cells. We used β-actin (primers: forward 5’TCGTGGGCCGCTCTAGGCACCA-3’ and reverse 5’GTTGGCCTTAGGGTTCAGGGGGG-3’) as our reference gene. The qPCR was carried
out using Quantifast SYBR Green master mix (Qiagen, Mississauga, ON) on a Miniopticon cycler (Bio-Rad, Mississauga, ON). We used the following cycling protocol:
95°C for 5 min and then 40 cycles of 95°C for 10 s, 60°C for 30 s and 80°C for 30 s.
SYBR green fluorescence was acquired at 80°C in each amplification cycle.
Subsequently a melt curve was generated, starting at 60°C and taking measurements
every 0.2°C until 95°C was reached.

2.2.3 Protein content
Skeletal muscle and liver were homogenized in sodium dodecyl sulfate (SDS) lysis buffer
with protease inhibitor cocktail (Sigma-Aldrich). After centrifugation, protein
concentrations were determined using a Bradford protein assay. Equal amounts of protein
were loaded on a 10% polyacrylamide gel followed by gel electrophoresis and transfer to
a PVDF membrane. The membrane was blocked with 3% bovine serum albumin
overnight, followed by incubation with primary H-135 PAI-1 antibody and mouse antirabbit horseradish peroxidase secondary antibody (Santa Cruz Biotechnology, Santa
Cruz, CA) for one hour each. The membrane was then treated with Western Lighting
Chemiluminescence reagent (Perkin Elmer, Woodbridge, ON) and exposed to Kodak
Biomax MR film (Carestream Health, Rochester, NY). We then stripped the membrane
using stripping buffer and reprobed it for β-actin using anti-actin CP01 primary and IgM
anti-mouse J1200 secondary antibodies (Calbiochem, La Jolla, CA). To determine the
PAI-1 protein level in muscle homogenates by enzyme-linked immunosorbent assay
(ELISA), we used muscle from mice where blood was flushed out with saline by means
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of abdominal aortic cannulation and cutting of the vena cava. To determine the PAI-1
protein level in plasma, we centrifuged systemic whole blood and used PAI-1 ELISA (for
either total (all PAI-1 present in the sample including complexed with t-PA or u-PA) or
active (only biologically active PAI-1 in the sample) PAI-1). PAI-1 ELISA kits were
purchased from Innovative Research (Novi, MI). Finally, the plasmin anti-plasmin (PAP)
complex level in plasma was measured with an ELISA kit from Cusabio Biotech
(Newark, NJ).

2.2.4 Fibrin zymography
We used modified fibrin zymograph gels to examine the PAI-1 protein activity in skeletal
muscle and liver tissues. Typically, the gel is prepared to include fibrinogen,
plasminogen, thrombin and u-PA to induce plasmin-mediated fibrin degradation. The
tissue sample is then run on the gel and the capacity of the PAI-1 in the sample to inhibit
the u-PA-induced fibrin degradation is assessed (5). In the present study, instead of
embedding u-PA in the gel, we mixed a known amount of u-PA with the sample and
incubated the mixture for 5 minutes. We then ran this mixture, and u-PA alone, on
separate lanes on the gel and assessed PAI-1 activity in the sample by comparing fibrin
degradation caused by the mixture against degradation caused by u-PA alone. Again, the
PAI-1 activity in the sample was revealed by inhibition of u-PA-induced fibrin
degradation.
Briefly, skeletal muscle and liver tissues were homogenized in Tris-NaCl-Triton-EDTA
(TNTE) buffer. The homogenate (40 µl of total volume) including 50 µg of protein, 20 µl
of non-denaturing loading buffer and 0.001 U of u-PA (all from Sigma-Aldrich) was
resolved on a 10% SDS PAGE gel. To confirm the presence of fibrin in the gel (through
its digestion), and as a method of standardization, 40 µl of homogenization buffer, 20 µl
of non-denaturing loading buffer and 0.001 U of u-PA were mixed together and loaded in
an empty lane on the gel. The gel contained 1.2 mg/ml human fibrinogen (from
Calbiochem), 0.06 U/ml human plasminogen and 0.25 U/ml human thrombin (both from
Sigma-Aldrich). As human and mouse fibrinolytic factors have been demonstrated to
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cross-react (5), human factors were used as a substitute for the extremely limited
availability of comparable mouse fibrinolytic factors. The SDS in the gel was exchanged
with 2.5% Triton X-100 for 1 h. The gel was then incubated in developing buffer (30 mM
Tris, 200 mM NaCl, pH 7.4) for 24 h (all from Sigma-Aldrich). The gel was stained with
Coomassie blue R-250 (Bio-Rad) staining solution for 20 minutes, then destained and
imaged on the Bio-Rad GS-690 imager. Densitometry was completed using the MultiAnalyst 1.1 software package (Bio-Rad).

2.2.5 Platelet count in septic blood
We used heparanized blood samples diluted 200-fold in saline, labeled platelets therein
with rhodamine 6G (0.4 µg/mL, Sigma-Aldrich) or calcein-AM (8 µM, Sigma-Aldrich)
and counted them in a hemocytometer chamber under a microscope.

2.2.6 Thrombelastography (TEG)
Concurrently with the platelet count, TEG was used to measure coagulability in systemic
blood. An aliquot of 360 µL of the heparinized systemic blood was added to a prewarmed heparinase cuvette of the TEG machine (type 5000, Hemonetics, Braintree, MA)
and analyzed according to manufacturer’s instructions. In principle, TEG measures the
developed mechanical strength of the formed blood clot after the onset of clotting, and it
yields parameters reflecting the speed of clotting and the maximal clot strength (13).

2.2.7 Statistical analysis
Data are presented as mean ± SE; n indicates the number of mice per treatment. One
skeletal muscle or liver sample was used per mouse. Data were analyzed using one-way
ANOVA (repeated measures ANOVA for ex vivo model) followed by two-tail test with
Bonferroni correction for multiple comparisons, with a level of significance of p < 0.05.
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2.3 RESULTS

2.3.1 Effect of streptokinase on capillary plugging
Intravital microscopy at 7 h post-FIP showed that sepsis markedly increased the number
of stopped-flow capillaries in the skeletal muscle (Figure 2.1). Streptokinase, a putative
pro-fibrinolytic agent, reduced this number, suggesting that fibrinolysis plays a role in the
restoration of capillary blood flow. Since ascorbate similarly reduced the number of
stopped-flow capillaries (Figure 2.1), we pursued the testing of our hypothesis that
ascorbate has a pro-fibrinolytic effect in the septic microvasculature. In principle,
ascorbate could achieve this effect by elevating the local t-PA and u-PA levels and/or by
inhibiting the local PAI-1.

2.3.2 Effect of sepsis on pro-fibrinolytic factors in the skeletal muscle
Sepsis did not statistically alter t-PA mRNA in skeletal muscle homogenate when
compared to control; ascorbate did not affect the septic level of t-PA mRNA (P = 0.15,
Figure 2.2a). Sepsis increased u-PA mRNA expression in muscle but ascorbate failed to
alter this increased level (Figure 2.2b). This lack of effect of ascorbate was inconsistent
with our hypothesized pro-fibrinolytic effect of ascorbate via increased u-PA level alone.
Similar to the muscle homogenate, there was no effect of sepsis and ascorbate on t-PA
mRNA in freshly isolated endothelial cells (major source of pro- and anti-fibrinolytic
factors) (Figure 2.2a). Sepsis increased u-PA mRNA in the endothelial isolates, but cells
from septic mice treated with ascorbate failed to alter this increase (Figure 2.2b).

2.3.3 Effect of sepsis on the anti-fibrinolytic factor PAI-1
In muscle homogenates, sepsis increased PAI-1 mRNA when compared to control;
ascorbate inhibited this increase (Figure 2.3a). In endothelial isolates, no effects of sepsis
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Figure 2.1 Ascorbate and streptokinase reduce the sepsis-induced increase in
stopped-flow capillaries. Sepsis was induced by fecal injection into peritoneum (FIP).
At 7 h post-FIP, the mouse hindlimb skeletal muscle capillary perfusion was observed
using intravital microscopy. There was an increase in stopped-flow capillaries in septic
mice. Ascorbate (10 mg/kg) or streptokinase (25000 U/kg), but not saline injected
intravenously at 6 h reduced the blood flow stoppage in capillaries. * compared to
control, # compared to sepsis+saline group, P < 0.05, n = 7 - 9 mice/group.
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Figure 2.2. Effect of sepsis and ascorbate on t-PA and u-PA mRNA expression in
mouse skeletal muscle. Panel a: Sepsis at 7 h did not affect t-PA mRNA in muscle
homogenates or in endothelial isolates from this muscle. Panel b: Sepsis increased u-PA
mRNA in the muscle and in cell isolates. Ascorbate injected at 6 h did not affect t-PA and
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isolates (both panels).
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Figure 2.3. Effect of sepsis and ascorbate on PAI-1 mRNA in mouse skeletal muscle,
and on PAI-1 protein in muscle and blood plasma. Panel a: Ascorbate injected at 6 h
inhibited the sepsis-induced increase in PAI-1 mRNA expression in muscle homogenates
at 7 h. Based on western blot analysis (Panel b) or ELISA (Panel c), neither sepsis nor
ascorbate affected PAI-1 protein expression in muscle homogenates. Panel d: Sepsis
increased PAI-1 protein in systemic blood plasma analyzed by ELISA at 7 and 9 h postFIP. Ascorbate injected at 6 h did not affect these PAI-1 protein increases. * P < 0.01
compared to control, # compared to sepsis+saline group, n = 8 - 9 mice/group for PAI-1
homogenates, 3/group for immunoblots, 4 -5/group for ELISA, and 5 - 7/group for
plasma.
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or ascorbate were observed (Figure 2.3a). Western blot and ELISA protein analyses of
muscle homogenates showed no increase in PAI-1 protein expression in sepsis and no
effect of ascorbate on protein levels (Figures 2.3b and 2.3c). Consistently, fibrin
zymography of muscle homogenates showed no effect of sepsis and ascorbate on
inhibition of u-PA-induced fibrin degradation (Figure 2.4a). However, total blood plasma
PAI-1 protein analysis by ELISA revealed a nearly 3-fold increase in PAI-1 in septic
mice at 7 h, and a 30-fold increase at 9 h. Ascorbate had no effect on these increases
(Figure 2.3d). ELISA analysis of activated PAI-1 in septic mice at 7 h (See Chapter 3,
Figure 3.3) showed a significant increase comparable to that of total PAI-1 protein shown
in Figure 2.3d.

2.3.4 PAI-1 expression in the liver
Similar to published reports on PAI-1 mRNA in various organs (27, 35), our preliminary
data in the septic mouse lung, heart, liver and kidney indicated that the liver is a major
source of PAI-1 (See Chapter 3, Figure 3.2). Indeed, sepsis increased PAI-1 mRNA in the
liver 6-fold, but only 2.5-fold in the skeletal muscle (Figures 2.3a, 2.6a). Ascorbate did
not affect the PAI-1 mRNA expression in the liver (Figure 2.6a). Almost identical to the
muscle western blot data (Figure 2.3b), our pilot western blots from liver homogenates
showed no effect of sepsis or ascorbate on PAI-1 protein level (Figure 2.5). However,
fibrin zymography of liver homogenates showed that sepsis increased the inhibition of uPA-induced fibrin degradation, while ascorbate failed to alter this effect (Figure 2.4b).
Consistent with the dominance of liver in total PAI-1 production during sepsis, the liver
homogenates showed a greater inhibition of u-PA-induced fibrin degradation than muscle
homogenates (Figure 2.4c).

2.3.5 Pro-fibrinolytic factor expression in the liver
In parallel to the increase in PAI-1 mRNA, t-PA mRNA and u-PA mRNA also increased
in the septic liver (Figures 2.6b, 2.6c). In contrast to the muscle, ascorbate inhibited the
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Figure 2.4. Effect of sepsis and ascorbate on PAI-1 protein activity in mouse skeletal
muscle and liver analyzed by fibrin zymography. Panel a: Zymograph 1 shows an
example of a fibrin zymograph gel used for analysis of PAI-1 activity in skeletal muscle
homogenates. In lane 1, exogenous u-PA in loading buffer (40 µl total volume) was run
on the gel. This u-PA resulted in plasmin-mediated fibrin degradation in the gel, seen as a
bright band at 33 kDa. In lane 2, the control mouse muscle homogenate was mixed with
the same amount of exogenous u-PA, and the mixture was run on the gel. When
compared with lane 1, the band in lane 2 was dimmer, indicating inhibition of u-PAinduced fibrin degradation (i.e., a measure of inhibition of exogenous u-PA by PAI-1
present in the muscle sample). We used densitometry to set u-PA inhibition to 0 % when
the sample band brightness was equal to that in lane 1, and to 100 % when the sample
band brightness was equal to that of gel background. In lanes 3 and 4, we mixed u-PA
with septic muscle homogenate from mice injected at 6 h with saline or ascorbate,
respectively. Below zymograph 1, the 3 bars show a comparable u-PA inhibition among
muscles from control, sepsis+saline and sepsis+ascorbate groups. Panel b: Zymograph 2
shows an example of a fibrin zymograph in liver homogenates. With reference to lane 1,
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a larger u-PA inhibition was seen in septic liver (lane 3) than in control liver (lane 2).
Ascorbate treatment did not alter the sepsis-induced increase in u-PA inhibition. To
compare PAI-1 activity between the muscle and liver (sepsis+saline groups), we ran an
extra lane with liver in zymograph 1 (lane not shown) and compared this lane and lane 3
with reference to lane 1. Panel c summarizes this comparison, showing a larger u-PA
inhibition for septic liver than muscle. In each zymograph, the lanes were not run
adjacent to each other. The spaces between lanes were cropped. * P < 0.05 compared to
control, # P < 0.05 compared to septic muscle group, n = 5 - 6 mice/group.
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Figure 2.5. Effect of sepsis and ascorbate on the PAI-1 protein expression in the
liver. In a pilot experiment, mice were injected with saline or ascorbate at 6 h post-FIP.
Neither sepsis nor ascorbate affected PAI-1 protein expression by western blotting in
liver homogenates. In the western blot, the lanes were not run side-by-side and therefore
the lanes inbetween were cropped. n = 2-3 mice/group.
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Figure 2.6. Effect of sepsis and ascorbate on PAI-1 (Panel a), t-PA (Panel b), and uPA (Panel c) mRNA expression in mouse liver. Sepsis increased PAI-1, t-PA, and uPA mRNA expression. Ascorbate inhibited the increase in t-PA expression. * P < 0.05
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sepsis-induced increase in t-PA mRNA in the liver (Figure 2.6b). However, the sepsisinduced increase in u-PA mRNA was unaffected by ascorbate in the liver (Figure 2.6c).

2.3.6 Plasmin anti-plasmin expression in the septic blood
To determine whether the parallel increase in pro- and anti-fibrinolytic factors in liver
mRNA resulted in an overall pro-fibrinolytic or anti-fibrinolytic effect, we used ELISA
to measure the protein level of the PAP complex (an index of fibrinolysis by plasmin) in
the systemic blood samples. Sepsis dramatically reduced the PAP level; ascorbate did not
affect this response (Figure 2.7).

2.3.7 Alterations in platelet count in the septic blood
Analysis of systemic blood revealed a significant sepsis-induced 34 % drop in platelet
count; ascorbate injection increased the platelet count by 23% when compared to the
sepsis+saline group (Figure 2.8).

2.3.8 Thrombelastography of septic blood
Finally, we used TEG to measure coagulability in systemic arterial blood. Sepsis reduced
the maximal clot strength at 6 h. Ascorbate injected at 5 h did not alter this clot strength
(Figure 2.9 and Table 2.1).
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Figure 2.7. Effect of sepsis and ascorbate on plasmin-antiplasmin (PAP) in systemic
blood. Sepsis reduced PAP. Ascorbate did not affect this reduction. * P < 0.05
compared to control, # P < 0.05 compared to the sepsis+saline group, n = 6 mice/group.
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Figure 2.8. Effect of sepsis and ascorbate on platelet count. Sepsis reduced the
platelet count in mice. Ascorbate partially restored the platelet count. * P < 0.05
compared to control, # P < 0.05 compared to the sepsis+saline group, n = 8 mice/group
for platelet count.
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Figure 2.9. Examples of thrombelastography tracings from systemic blood samples
obtained from control mice and septic mice at 6 h where saline was injected
intravenously at 5 h. R is the reaction time to initial clot formation, K is the kinetic time
from the beginning of clot formation until the amplitude reaches 20 mm, α angle reflects
the initial rate of force development (i.e., clotting speed) and MA is the maximum
amplitude of clot strength.
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Table 2.1. Summary of thrombelastography parameters from control, sepsis+saline,
and sepsis+ascorbate groups (mean ± SE). The TMRTG and MRTG have been
estimated from the TEG tracing.

control

R

K

α angle

(min)

(min)

13 ± 3

MA

G

TMRTG

MRTG

(degrees) (mm)

(kd/s)

(min)

(100*mm/s)

7±1

33 ± 4

66 ± 2

10 ± 1

6±2

6±1

17 ± 8

13 ± 5

23 ± 7

46 ± 5 *

5 ± 1 * 11 ± 6

5±2

20 ± 5

11 ± 5

25 ± 6

47 ± 6 *

5±1* 7±1

5±1

(n=5)
sepsis+saline
(n=5)
sepsis+ascorbate
(n=5)

* P < 0.05 compared to control. R - reaction time to initial clot formation, K - kinetic
time from the beginning of clot formation until the amplitude reaches 20 mm, α angle initial rate of force development, MA – maximum amplitude, G – shear elastic modulus
strength, TMRTG – time to maximum rate of thrombus generation, MRTG - maximum
rate of thrombus generation
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2.4 DISCUSSION

The present study employed a model of severe sepsis (80 % mortality at 24 h, (30))
associated with a marked drop in platelet count and systemic blood hypo-coagulability.
The study examined for the first time the capillary bed perfusion in skeletal muscle in the
context of consumption coagulopathy (i.e., DIC), including the role of fibrinolytic factors
produced in the muscle and a mechanism of an antioxidant defense against capillary
plugging through enhanced fibrinolysis. Analysis of the muscle tissue mRNA indicated
that the antioxidant ascorbate did not affect the t-PA and u-PA levels in sepsis but it
inhibited the PAI-1 level, resulting in a net pro-fibrinolytic effect in sepsis at the mRNA
level. However, analyses of muscle and liver homogenates, and of systemic blood in
septic mice, indicated no effect of ascorbate on (i) PAI-1 protein or its enzymatic activity,
(ii) PAP protein, and (iii) blood hypo-coagulability assessed by TEG. Together, these
results did not support the hypothesis that ascorbate promotes fibrinolysis in sepsis.

2.4.1 Disseminated intravascular coagulation in the capillary bed
DIC, a clinical condition in severe sepsis, has been explained by consumption
coagulopathy where platelets and coagulation factors are depleted from systemic blood,
resulting in a high risk for bleeding (11). Importantly, decreasing systemic platelet count
correlates with increasing mortality rate (17). To our knowledge, DIC has not been
examined directly at the level of capillary bed. There is qualitative histological evidence
of fibrin deposition in arterioles (11), but such deposition may not lead to stopped blood
flow and trapping of coagulation factors in the septic microvasculature. We reported that
sepsis stops flow in capillaries but not in the feeding arterioles or draining venules (25).
Therefore, the capillary bed may represent a unique micro-environment in the context of
DIC.
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2.4.2 Methodological considerations
Studies of sepsis are difficult given the complexity of the septic process itself (14) and
the experimental shortcomings of animal models of sepsis. A considerable challenge is
the animal-to-animal variability when determining the various end-points in sepsis (e.g.,
PAI-1 mRNA (7)). In the present study we aimed to reduce the variability of the
fibrinolytic factors by studying septic mice whose capillary blood flow stoppage was at
least 30 % (i.e., one standard deviation below the mean of 48 %, Figure 2.1). In spite of
this step, the present study showed a large variability in fibrinolytic factors, including the
variability in PAI-1 mRNA and protein expression (i.e., 5 to 7-fold differences between
minimal and maximal values in particular groups, precluding reaching statistical
significance between groups). This level of variability has been reported for mRNA of
fibrinolytic factors (7). The Ct values for the muscle and liver PAI-1 and β-actin were
23.4 ± 0.3, 18.6 ± 0.7, 24.3 ± 0.6 and 18.0 ± 0.9, respectively. The β-actin levels were
observed to be similar between sham and septic groups.

2.4.3 Pro-fibrinolytic factors in tissue
Little is known about the pro-fibrinolytic factors in the septic microvasculature. The
present data from muscle and liver (Figures 2.2a, 2.6b) agree with reports that sepsis
either increases or causes no change in t-PA mRNA and protein levels in mice and rats
(16, 21). The presently observed u-PA mRNA increases in muscle and liver homogenates
of septic mice also agree with lipopolysaccharide (LPS)-induced increases in u-PA
mRNA in various tissues in mice (35) and in sepsis-induced increases in u-PA plasma
protein levels in humans (23).

2.4.4 Anti-fibrinolytic factors in tissue
Increased anti-fibrinolytic PAI-1 mRNA and protein expression have been reported for
both septic patients (18) and animal models of sepsis (35). Our PAI-1 mRNA/ELISA
protein data from plasma agree with these reports, but our PAI-1 protein data based on
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western blot/ELISA analysis of tissue homogenates do not. We explain these data by
noting that PAI-1 protein could be rapidly externalized and shed into blood stream (19),
and/or released into blood from platelets (3), making the sepsis-induced increase in PAI-1
protein preferentially detectable in blood plasma rather than in tissue.
We used the fibrin zymography as an alternative approach to study the effect of sepsis on
PAI-1 protein function. This approach does not measure PAI-1 activity directly, but
rather it assesses the ability of PAI-1 in the homogenate to inhibit u-PA-induced fibrin
degradation in the gel (10). Our zymographs showed that sepsis increased the inhibition
of u-PA in the liver but not muscle (Figures 2.4a and 2.4b). This is consistent with the
dominant role of liver in PAI-1 production during sepsis. However, in view of the data in
Figure 2.4b, it is puzzling why western blot analysis failed to detect a sepsis-induced
increase in PAI-1 protein even in this dominant organ. When considering the large
change in PAI-1 mRNA detected by qPCR in the liver (Figure 2.6a), it is possible that the
western blot in this tissue may not have been sensitive enough to detect the corresponding
change at the protein level. Thus, the modest increase seen in PAI-1 mRNA in the muscle
(Figure 2.6a) might have resulted in a corresponding protein change undetectable by
western blot or zymography (Figure 2.4a). Regarding the discrepancy between the effect
of ascorbate on PAI-1 mRNA and protein expression, I discuss the possibility of a delay
of the effect of ascorbate on the protein expression in blood plasma in section 5.2.4.

2.4.5 Pro- versus anti-fibrinolytic factors in septic systemic blood
Sepsis increases both u-PA and PAI-1 plasma protein levels (9). In humans injected with
tumor necrosis factor (TNFα), the plasma PAP level rises but then it returns towards
control (32), indicating a transient increase in fibrinolysis by plasmin in systemic blood.
This transient characteristic of PAP could be due to the delayed surge of PAI-1 (31), the
inhibitor of u-PA (9). In the present study we found that PAP level was markedly reduced
at 7 h of sepsis (Figure 2.7), indicating that the large increase in plasma PAI-1 protein
(Figure 2.3d) precipitated inhibition of fibrinolysis in systemic blood at this time.
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2.4.6 Effect of ascorbate on fibrinolytic factors in sepsis
We observed that ascorbate did not affect the sepsis-induced u-PA mRNA increase in the
muscle or liver. However, ascorbate inhibited the sepsis-induced PAI-1 mRNA increase
in the muscle but not liver. These findings are consistent with a pro-fibrinolytic effect of
ascorbate in muscle (i.e., maintenance of elevated u-PA and lowering its inhibitor PAI-1).
However, analyses of PAI-1 protein/enzymatic activity in muscle and liver homogenates,
and of systemic blood in septic mice, indicated no effect of ascorbate. Thus, the protein
data do not support the hypothesis that ascorbate promotes fibrinolysis during sepsis.

2.4.7 Hyper-coagulation in the microcirculation versus hypocoagulation in systemic circulation in sepsis
Severely septic patients with DIC present with a low platelet count (17), hypocoagulability of systemic blood as assessed by TEG, and high risk for bleeding (28). The
present septic mice also showed lowered platelet count and TEG hypo-coagulability
(Figures 2.8, 2.9 and Table 2.1). However, these observations disagree with our recent
report of hyper-coagulability of blood in capillaries of skeletal muscle in septic mice,
where increased platelet adhesion, fibrin deposition and propensity to form microthrombi in these capillaries were noted (25). This apparent disagreement could be
explained in terms of the concept of DIC where platelets and coagulation factors are
trapped in the microcirculation and thereby depleted from systemic blood which then
inevitably becomes hypo-coagulable. To our knowledge, however, this possible
redistribution between micro- and macrocirculation during sepsis has not been addressed
experimentally. There is some indirect evidence for this redistribution. Fisher and
coworkers reported that FIP-injected mice demonstrated severe hypo-coagulability of
systemic blood (TEG, prothrombin time, activated partial thromboplastin time measures),
and that ascorbate injection completely protected against this hypo-coagulability (6).
In the present study, ascorbate reversed the low platelet count in sepsis toward the
control level (Figure 2.8). We interpret these data to indicate that the observed beneficial
effect of ascorbate (i.e., restoration of capillary blood flow in sepsis) could be at the level
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of platelet adhesion rather than fibrinolysis. Recently, we showed that ascorbate reduces
platelet aggregation and expression of the adhesion molecule P-selectin in an ex vivo
model of sepsis (26). Clearly, there may be other mechanisms whereby ascorbate
prevents/reverses capillary plugging (26, 34).
In conclusion, we hypothesized that 10 mg/kg ascorbate injection delayed for 6 h
after the onset of sepsis has a fibrinolytic effect in the septic microvasculature. Based on
the various approaches used to examine PAI-1 protein levels in plasma, and muscle and
liver homogenates we failed to demonstrate any effect of the delayed ascorbate dose on
these levels.
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Chapter 3

Ascorbate does not alter bacterial content, plasminogen
activator inhibitor-1, and myeloperoxidase levels in septic
mouse organs

A version of this chapter has accepted for publication in Journal of Surgical Research
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3.1 INTRODUCTION

Sepsis, a systemic inflammatory response to an infection, has many detrimental effects on
the cardiovascular system. These include hypotension, reduced vascular reactivity and
reduced capillary bed perfusion (19, 28, 31, 32). The precise mechanism of reduced
capillary perfusion is unknown, but an activated coagulation system including
microthrombi formation in capillaries has been suggested (28, 29). Sepsis elevates PAI1, which may lead to inhibited fibrinolysis and subsequent stabilization of microthrombi
and plugging of capillaries (24, 30, 38). However, data from PAI-1 knockout mice
suggest elevated PAI-1 during sepsis may be beneficial as survival from sepsis was
reduced in these knockout mice (13, 16). These studies indicate the complexity of the
effects of sepsis on the coagulation system in various organs.
Sepsis is associated with marked reduction in plasma ascorbate (reduced form of
vitamin C), which has been associated with poor outcome in sepsis (27). Importantly,
studies in mouse models of sepsis demonstrated that injection of an ascorbate bolus
reduces organ injury and mortality in sepsis (8, 32, 34). We have shown that ascorbate
injection prevents and reverses capillary plugging in the septic mouse skeletal muscle by
decreasing platelet activation and platelet-endothelial cell adhesion (28, 29, 32).
Furthermore, antioxidant therapy in septic rats reduced organ dysfunction from oxidative
damage caused by neutrophils, consistent with the beneficial effect of ascorbate (2).
However, since ascorbate could alter the coagulation system (14, 29), the question arises
as to whether it could negatively affect the beneficial role of PAI-1 in sepsis. For
example, Jaulmes and colleagues showed that PAI-1 expression depends on NADPH
oxidase activity (14), which can be inhibited by ascorbate (33). Given the apparent
requirement for PAI-1 in survival during sepsis (16), ascorbate could thus indirectly
reduce survival by inhibiting PAI-1. Also, because PAI-1 is required for normal
neutrophil efferocytosis (23) and infiltration (18), inhibition of PAI-1 by ascorbate could
compromise the neutrophil-mediated immune response in infected organs. Ascorbate has
bactericidal properties at very high levels, raising the possibility that the reduced
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mortality observed with ascorbate treatment could be due to reduced bacterial loads (12,
37). However, no apparent bactericidal effect of ascorbate in the peritoneum of septic
mice has been reported (34).
To investigate the mechanisms of action of ascorbate, our objective was to determine its
effect on bacterial content, PAI-1 levels and neutrophil infiltration in septic mice. Based
on the fact that ascorbate reduces mortality in sepsis, and that PAI-1 is needed for
survival, we hypothesized here that ascorbate does not alter the PAI-1 expression and
neutrophil infiltration in organs with presumed high immune response in sepsis (lung,
kidney, spleen, liver), preserving the beneficial effect from PAI-1.

3.2 METHODS

3.2.1 Animal model of sepsis
All experiments were performed with approval of the University of Western Ontario
Council on Animal Care. Male C57BL/6 mice were bred in our animal facility from
mice purchased from Jackson Laboratory (Bar Harbor, ME) or Charles River
(Sherbrooke, QC), and were housed in a controlled environment with a 12 h light/dark
cycle and access to food and water ad libitum. The mice used were between 2-3 months
old and between 20-25 g in weight. Feces was collected from the cecum of donor mice
and mixed in sterile saline at a concentration of 75 mg/ml and kept at 4°C. Mice were
anesthetized using a ketamine (80 mg/kg) and xylazine (4 mg/kg) mixture given via
intraperitoneal injection. Sepsis was induced in our mice by injecting the feces mixture
into peritoneum (FIP) as described previously (32). Alternatively, control sham mice
were injected with 1 ml sterile saline intraperitoneally. All mice were fluid resuscitated
subcutaneously with 1 ml saline containing 2 µg/ml buprenorphine as an analgesic.
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3.2.2 Experimental design
We have reported that intravenous injection of ascorbate delayed to 6 h of sepsis (i.e.,
when capillary plugging is prevalent) restores capillary blood flow in skeletal muscle by
7 h (28). This restoration of flow (or reversal of plugging) could be due to dissolution of
microthrombi through enhanced fibrinolysis due to inhibition of PAI-1 by ascorbate. In
the present study, we chose to study the effect of this delayed ascorbate injection. At 6 h
post-FIP, mice were anesthetized and then injected intravenously with 0.1 ml of sterile
saline or ascorbate (10 mg/kg); they remained under anesthesia for 1 h. Upon completion
of the 1 hour treatment time (7 h post-FIP), the blood, peritoneal fluid, lung, kidney,
spleen, liver, heart and the extensor digitorum longus skeletal muscle were harvested.
We chose lung, kidney, spleen and liver because these organs were suspected to be
involved in neutrophil recruitment and immune response during sepsis (1, 36). We chose
the skeletal muscle because in our previous studies we focused on the microcirculatory
response of this organ during sepsis (28, 32); the heart presented another type of muscle
to compare with skeletal muscle.

3.2.3 Tissue and blood collection
All chemicals were from Sigma-Aldrich (Oakville, ON) unless otherwise noted. The
carotid artery blood was collected 9:1 in acid citrate dextrose solution while peritoneal
fluid was diluted with 2 ml sterile saline and collected to determine the bacterial load.
The organs located in the peritoneum were washed twice with sterile saline to remove
peritoneal fluid from their exterior. Samples were stored in RNAlater for mRNA
analysis, frozen at -80°C for protein analyses, or processed for assessing their bacterial
content. Samples were diluted 1:5 in sterile saline, homogenized, serially diluted in 10fold fashion, and plated on Columbia Blood Agar containing 5% sheep blood (MP0351,
Oxoid, Nepean, ON) and grown overnight at 37°C. The bacterial colony forming units
(CFU) were counted and normalized to the CFU determined in the peritoneal fluid.
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3.2.4 PAI-1 mRNA and protein quantification
mRNA was isolated from homogenized tissues using Trizol (Invitrogen) and chloroform
as directed by the manufacturer. The isolated mRNA was reverse transcribed using
Superscript II (Invitrogen), then quantified using Quantifast SYBR Green (Qiagen,
Mississauga, ON) on a Bio-Rad CFX96 thermal cycler (Bio-Rad, Mississauga, ON). The
following primers were used to detect PAI-1: (primers: forward 5’GACAGCACTGTCAGGGTCCATAG-3’ and reverse 5’GCGGTCCTCCTTCACAAAGCTC-3’). β-actin (primers: forward 5’TCGTGGGCCGCTCTAGGCACCA-3’ and reverse 5’GTTGGCCTTAGGGTTCAGGGGGG-3’) was used as a reference gene. The following
cycling protocol was used to amplify the target genes: 95°C for 5 min and then 40 cycles
of 95°C for 10 s, 60°C for 30 s and 80°C for 30 s.
Blood in citrate was centrifuged at 6000g for 10 minutes and the plasma retained
for active PAI-1 protein measurement by ELISA as directed by the manufacturer
(MPAIKT, Molecular Innovations, Novi, MI). PAI-1 enzymatic activity was determined
by reverse fibrin zymography (5, 17). Briefly, 10% SDS PAGE gels were impregnated
with human fibrinogen (1.2 mg/ml, Calbiochem), 0.06 U/ml human plasminogen and
0.25 U/ml human thrombin. Tissues were homogenized in Tris-NaCl-Triton-EDTA
buffer, 100 µg of protein was incubated for 5 minutes with 0.001 U exogenous u-PA,
mixed with 20 µl of non-reducing loading buffer and run on the SDS PAGE gel. The
SDS in the gel was substituted with 2.5% Triton X-100 for 1 h, then developed for 24 h
in developing buffer (30 mM Tris, 200 mM NaCl, pH 7.4). Gels were stained with
Coomassie blue then destained and densitometric analysis was conducted using MultiAnalyst 1.1 software (Bio-Rad).

3.2.5 Neutrophil infiltration in organs
Neutrophil infiltration in organs was measured using a myeloperoxidase (MPO) assay,
which is a conventional method for assessing this infiltration (22). Frozen tissues were
homogenized in 20 mM potassium phosphate buffer and centrifuged at 6000g for 20
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minutes. The supernatant was then discarded and the pellet was resuspended in 50 mM
acetic acid with 0.5% hexadecyltrimethylammonium hydroxide detergent. The samples
were then sonicated for 10 s and centrifuged for 5 minutes. The supernatants were mixed
with a 1 mM TMB and 0.2 M acetic acid solution, warmed to 37°C, and the reaction
initiated with the addition of 3 mM H2O2. The samples were left to react for 5-30
minutes (depending on the tissue), then quenched using 1000 U/ml beef catalase and 0.2
M acetic acid. Spectrophotometric analysis was conducted using the Model 680
microplate reader and software version 5.2.1 (Bio-Rad) at 655 nm and compared to an
MPO standard.

3.2.6 Statistical analysis
Data are presented as mean ± SE. One sample of each organ was used per mouse.
Statistical analysis was conducted using one-way ANOVA and the Bonferroni multiple
comparison test. Results were deemed significant with a P < 0.05.

3.3 RESULTS

3.3.1 Bacterial content
Samples from sham peritoneal fluid showed zero or very low CFUs (0.002 ± 0.002
CFU/µl (n = 13)), most likely resulting from occasional external contamination during
sample collection/handling. Septic mice had peritoneal fluid bacterial counts of 40,300 ±
19,100 CFU/µl (n = 14). We noted about a 7,000 fold range (with respect to the
minimum and maximum counts) in these counts despite injecting each mouse with the
same amount of feces. When feces were grown separately on agar gels, the bacterial
counts were 570 ± 190 CFU/µl of feces suspension (70 fold range with respect to the
minimum and maximum counts). Ascorbate injection at 6 h post-FIP did not
significantly alter the peritoneal fluid bacterial count. We observed that bacterial counts
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were significantly increased in septic mouse blood and all organs compared to sham
mice, with the highest mean count observed in the spleen and lowest in the muscle
(Figure 3.1). Ascorbate significantly lowered the bacterial count in the blood only.

3.3.2 PAI-1 mRNA expression and enzymatic activity
In control sham mice, the individual mRNA levels in organs were normalized to the
mean mRNA level found in each organ. Thus the normalized control levels were 1 ±
0.18 (lung), 1 ± 0.29 (kidney), 1 ± 0.16 (spleen), 1 ± 0.76 (liver), 1 ± 0.16 (heart), and 1 ±
0.14 (muscle). Figure 3.2 shows the fold increase in PAI-1 mRNA expression (relative to
the control level) in septic organs from mice treated with saline or ascorbate at 6 h postFIP. We observed sepsis-induced increases in PAI-1 in the lung, kidney, spleen, liver
and skeletal muscle. Ascorbate lowered this increase only in the muscle. Using an active
PAI-1 ELISA, we determined that sepsis significantly increased the blood plasma active
PAI-1 protein; ascorbate did not affect this increase (Figure 3.3). Our preliminary
experiments showed that the ELISA or western blotting approaches were insensitive to
detect changes in PAI-1 protein in the organs. For this reason, we used reverse fibrin
zymography to indirectly measure PAI-1 enzymatic activity in an organ sample. The
PAI-1 activity in the sample mixed together with exogenous u-PA was assessed by the
degree of inhibition of u-PA in terms of the degree digestion of the fibrin zymograph
(Figure 3.4). Figure 3.5 shows that sepsis increased u-PA inhibition in the lung, heart
and liver samples, indicating increased PAI-1 activity in these organs. Sepsis did not
affect u-PA inhibition in the kidney, spleen and skeletal muscle. Ascorbate did not affect
the sepsis induced changes in u-PA inhibition in any organs (Figure 3.5).

3.3.3 Neutrophil infiltration in organs
Figure 3.6 shows that sepsis increased the MPO levels in the lung and liver, while the
level was reduced in the spleen. No change in the MPO level was observed in the heart,
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Figure 3.1. Increased bacterial content in septic mouse organs is not altered by
ascorbate. Sepsis was induced by feces injection into the peritoneum (FIP). At 6 h mice
were injected i.v. with saline or ascorbate. At 7 h post-FIP, the peritoneal fluid and
carotid artery blood were collected, the organs harvested and homogenized, and then
plated on Columbia blood agar and cultured for 18 h. Bacterial content in fluids and
organs in control sham mice was either zero or negligibly small (data not shown).
Bacterial content in all septic fluids and organs significantly increased compared to
control (P < 0.001). Closed symbols are those of sepsis+saline mice, whereas open
symbols are those of sepsis+ascorbate mice. The bacterial content in septic blood was
significantly reduced by ascorbate. Several organ bacterial counts were calculated to be 0
and are not included in the figure: two data points in the blood, lung, heart and muscle
sepsis + saline groups, one in the kidney and liver sepsis + saline groups and two in the
muscle sepsis + ascorbate group. * P < 0.05 compared to sepsis + saline. The P values
for comparisons between sepsis + saline and sepsis + ascorbate groups were: 0.32 (lung),
0.99 (kidney), 0.27 (spleen), 0.31 (liver), 0.23 (heart), and 0.21 (muscle). The respective
sample sizes for sham, sepsis + saline and sepsis + ascorbate groups were 13, 14, 15
(blood), 13, 14, 15 (lung), 13, 14, 14 (kidney), 10, 11, 11 (spleen), 13, 15, 15 (liver), 13,
14, 15 (heart), 13, 15, 15 (muscle) mice.
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Figure 3.2. Sepsis increases PAI-1 mRNA in organs. Mice were treated as described
in Figure 3.1 and RNA was quantified using real time qPCR. The level of mRNA
expression in control sham mouse organs was set to 1. Fold increase in PAI-1 mRNA in
the septic muscle was inhibited by ascorbate. * P < 0.05 compared to control sham level.
# P < 0.05 compared to sepsis + saline fold change. The respective sample sizes for
sham, sepsis + saline and sepsis + ascorbate groups were 5, 5, 6 (lung), 7, 6, 7 (kidney),
8, 7, 8 (spleen), 8, 7, 7 (liver), 6, 5, 7 (heart), 8, 8, 9 (muscle) mice.
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Figure 3.3. Ascorbate does not affect increased PAI-1 protein in septic plasma.
Active PAI-1 protein content in 7 h post-FIP septic mice was measured by ELISA. There
was no significant difference between sepsis + saline and sepsis + ascorbate. * P < 0.05
compared to control sham. n = 4 mice per treatment.
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Figure 3.4. An example of reverse fibrin zymography of the mouse heart. In u-PA
lane, exogenous u-PA in loading buffer (40 µl total volume) was run on the gel. This
resulted in a bright band at 33 kDa, due to plasmin-mediated fibrin degradation in the gel.
In the sham lane, control sham mouse heart homogenate was mixed with an equal amount
of exogenous u-PA, and the mixture was run on the gel. When compared with the u-PA
lane, the sham band was darker, indicating inhibition of u-PA-induced fibrin degradation
(i.e., measuring inhibition of exogenous u-PA by the PAI-1 in the sample). Densitometry
was employed to set u-PA inhibition to 0 % when the band brightness was equal to that in
the u-PA lane, and to 100 % when the brightness was equal to that of the background. In
sepsis+saline and sepsis+ascorbate lanes, u-PA was mixed with septic heart homogenates
from mice injected with saline or ascorbate, respectively.

86

Lung

*

80

40
20

20

Sham

20

60

40

20

Sham

Sepsis
Sepsis
+Saline +Ascorbate

Sepsis
Sepsis
+Saline +Ascorbate

*

*

60
40
20

Sham

Sepsis
Sepsis
+Saline +Ascorbate

Muscle

100

u-PA inhibition (% )

80

Sham

80

0

Sepsis
Sepsis
+Saline +Ascorbate

Kidney

100

0

40

100

u-PA inhibition (% )

u-PA inhibition (% )

40

*

Liver

Spleen

60

*

60

Sepsis
Sepsis
+Saline +Ascorbate

80

0

80

0

Sham

100

u-PA inhibition (% )

*

60

0

Heart

100

u-PA inhibition (% )

u-PA inhibition (% )

100

80

60

40

20

0

Sham

Sepsis
Sepsis
+Saline +Ascorbate

Figure 3.5. Sepsis increases PAI-1 activity in the lung, heart and liver. PAI-1
enzymatic activity in septic mice at 7 h was measured indirectly by reverse fibrin
zymography. There were no significant differences between sepsis+saline and sham and
between sepsis+saline and sepsis+ascorbate groups in the spleen. * P < 0.05 compared to
sham. The respective sample sizes were 5 (lung, muscle), 6 (liver), 7 (heart), 8 (kidney)
and 9 (spleen) mice.
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Figure 3.6. Ascorbate does not affect sepsis-induced increase in lung MPO activity,
nor decrease in spleen MPO activity. Neutrophil infiltration was determined through
an MPO assay in septic organs at 7 h, with saline or ascorbate treatment at 6 h.
Ascorbate did not affect MPO activity in any organ compared to sepsis + saline. * P <
0.05 compared to control sham. The respective sample sizes for sham, sepsis + saline
and sepsis + ascorbate groups were 10, 9, 9 (lung), 6, 6, 6 (spleen), 6, 6, 6 (liver), 4, 5, 5
(heart) mice.
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while the kidney and skeletal muscle samples yielded undetectable MPO levels.
Ascorbate did not alter the MPO level in any organ (Figure 3.6).

3.3.4 Relationship between MPO level and PAI-1 activity
Figure 3.7 plots the MPO values of Figure 3.6 against the PAI-1 activity data of Figure
3.5. There was a high linear correlation between these two data sets (slope is
significantly different from 0, R2 value = 0.79). When muscle and kidney data were
removed (due to inability to detect MPO), the R2 value was 0.75; however the slope was
not significantly different due to the reduced sample size. It should be noted that MPO
and PAI-1 activity measurements were not always collected from the same mice and
therefore I had to construct Figure 3.7 using the mean values of MPO and PAI-1 activity.

3.4 DISCUSSION
An intravenous ascorbate dose of 10 mg/kg (equivalent to approximately 700 mg in an
average human male) has been shown to improve capillary perfusion in septic mouse
skeletal muscle (28, 29, 32). This dose of ascorbate is clinically relevant as humans have
been treated with higher doses through parenteral nutrition (20). In the present study, we
found that this ascorbate treatment does not affect the bacterial content in the lung, heart,
kidney, spleen, liver or skeletal muscle, or PAI-1 mRNA expression/enzymatic activity
and neutrophil infiltration in septic mice. These results support our hypothesis that, in
parallel to the beneficial effect on capillary bed perfusion, ascorbate does not alter sepsisinduced increases in PAI-1 expression and neutrophil infiltration in the organs with high
immune response, preserving the beneficial effect of PAI-1 on the immune function.
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Figure 3.7. MPO content correlates with PAI-1 activity in septic mouse organs.
The mean fold change in MPO from all sepsis+saline mouse organs in Figure 3.6 was
plotted against the mean fold change in PAI-1 activity from Figure 3.5. Panel A: The
slope of the linear regression for sepsis+saline was significantly different from 0. The
fold change in MPO signals for muscle and kidney were set to 1 (MPO levels were
undetectable in these two organs). These results suggest that neutrophil recruitment is
related to the PAI-1 activity. Panel B: When muscle and kidney were removed from the
linear regression due to the inability to detect MPO, the R2 value was relatively
unchanged, however there were too few points for statistical analysis.
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3.4.1 Model of ascorbate administration in sepsis
The low ascorbate levels observed in septic patients (i.e., levels linked to poor outcome
(27)), can be reversed by parenteral nutrition containing large doses of ascorbate (10003000 mg/day) (20, 27). We and others have shown that a large dose of ascorbate (200
mg/kg) injected into mice at the onset of sepsis protects against the various detrimental
effects of sepsis, including high mortality (8, 9, 34, 35). We also showed that a lower
dose of ascorbate (10 mg/kg) has similar beneficial effects against sepsis and that these
effects are seen even when ascorbate injection is delayed six hours into sepsis (28, 32).
The model of delayed injection is clinically relevant for patients presenting with sepsis,
and therefore this model was chosen to study the effect of ascorbate in the present
investigation.

3.4.2 Methodological considerations
To our knowledge, this study characterized for the first time the effect of FIP on bacterial
content in the peritoneal fluid and various organs. This characterization was limited to
bacteria which grow on agar plates, including Escherichia, Staphylococcus and
Streptococcus bacterial strains (Certificate of Analysis, Oxoid). Surprisingly, despite
ensuring injection of identical amounts of feces solution into mice, there was a large
variability in the bacterial content of the peritoneal fluid at 7 h post-FIP (7,000 fold
range). Accordingly, the bacterial counts in organs also varied extensively
(approximately 100 fold range for each organ, Figure 3.1). This extensive mouse to
mouse variability has been observed in other models of sepsis (13, 26). We speculate
that the large variability in our FIP model was due to differences in the viability and type
of the bacteria in the feces solution (70 fold), variability in the local immune response at
the site of injection and in the spread of bacteria from the peritoneum to the blood and
organs. Clearly, the observed variability in the initiation of sepsis contributed to the
variability seen in the PAI-1 mRNA levels (Figure 3.2). This particular mRNA
variability is also consistent with the literature (10, 24). Regarding detection of
sepsis/ascorbate-induced changes in PAI-1 protein level in the various organs, for
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unknown reasons, our attempts to determine these changes by western blotting and
ELISA failed. We speculate that the inability to detect differences in PAI-1 protein
levels was due to the high basal levels of PAI-1 found in the non-vascular cells drowning
out the relatively small increase in PAI-1 in the vascular cells. Therefore, we used fibrin
zymography, where exogenous u-PA inhibition is an indirect measure of PAI-1 activity
in organ samples. The fibrin zymography detected sepsis-induced increases in PAI-1
activity in blood plasma, lung, heart and liver (Figure 3.5, 3.8 and 3.9).

3.4.3 Bacterial counts in septic organs
Among the organs studied, the highest levels of bacteria were found in the organs that
mount the greatest immune response (kidney, spleen and liver), while relatively few
bacteria were found in the skeletal muscle (Figure 3.1). Blood was also heavily infected
with bacteria (Figure 3.1). The lack of effect of ascorbate on peritoneal fluid bacterial
count is consistent with the reported lack of effect of ascorbate on this count in the septic
mouse (34). Previous reports have observed a bactericidal effect of ascorbate (3, 12, 37).
We speculate that the discrepancy between the effect of ascorbate on bacterial count in
blood (Figure 3.1) and peritoneal fluid could be due to a possible bactericidal
concentration of ascorbate in the blood post-intravenous injection..

3.4.4 PAI-1 expression and activity in organs
Sepsis-induced increases in PAI-1 mRNA expression in the lung, kidney and liver
(Figure 3.2) are consistent with increases reported by Raeven and colleagues (24).
Others have also observed increased PAI-1 mRNA expression in organs with high
immune activity during sepsis (25, 26). Ascorbate did not affect the increases in PAI-1
mRNA in the organs with high immune activity, but it inhibited the increase in PAI-1
mRNA in the skeletal muscle (Figure 3.2). It is possible that the effect of ascorbate on
PAI-1 mRNA expression differs depending on the immune activity in each organ. To our
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Figure 3.8. An example of reverse fibrin zymography of the mouse blood plasma.
Similar to the reverse fibrin zymography in Figure 3.4, exogenous u-PA was added to
blood plasma from 3 control sham mice (Sham 1, 2 and 3) and 3 sepsis + saline mice
(Sepsis 1, 2 and 3). Sham 1 and Sepsis 1, 2 and 3 lanes were darker than the exogenous
u-PA lane, indicating inhibition of exogenous u-PA by PAI-1 in these samples. Sham 2
and 3 had brighter bands than the exogenous u-PA band, indicating enhanced fibrin
degradation than by exogenous u-PA alone, most likely due to endogenous u-PA present
in these sham samples. According to the definition of exogenous u-PA inhibition in
Figure 3.4, negative values of u-PA inhibition were computed. Side by side comparison
between septic and sham mice clearly shows greater inhibition of exogenous u-PA in the
septic samples.
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data summarize the mouse blood plasma reverse fibrin zymography data exemplified in
Figure 3.8. These data agree with data from Figure 3.3, where an Active PAI-1 ELISA
showed a significant increase in PAI-1 protein expression in the blood plasma of septic
mice. A negative u-PA inhibition indicates a pro-fibrinolytic state, and a positive u-PA
inhibition indicates an anti-fibrinolytic state in the blood plasma. These data then
validate the use of reverse fibrin zymography to detect PAI-1 in samples. * P < 0.05
compared to sham. n = 6 mice per group.
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knowledge, the effect of ascorbate or other antioxidants on PAI-1 mRNA/protein
expression in septic organs has not been reported.
Our data showing sepsis-induced increases in active PAI-1 protein in blood
plasma (Figure 3.3) are consistent with previous reports (31). Ascorbate did not affect
this increase. Our preliminary unpublished data at 9 h post-FIP (ascorbate injected at 6 h)
also showed a lack of effect of ascorbate on sepsis-induced increase in PAI-1 protein,
indicating that even at 3 h post-injection, ascorbate does not affect PAI-1 protein
expression. Regarding PAI-1 enzymatic activity in organs measured by zymography,
ascorbate did not alter the levels observed during sepsis (Figure 3.5). Out of the six
organs examined, the sepsis-induced increased PAI-1 mRNA levels yielded increased
activities only in the lung and liver. The lack of increased enzymatic activity, despite
increased mRNA level in the kidney and skeletal muscle, suggests several possibilities
including decreased mRNA stability resulting in no PAI-1 protein production in certain
organs or an organ specific post-translational modification of PAI-1 protein in sepsis.
Interestingly, the PAI-1 activity in the septic heart increased despite unchanged mRNA
level in this organ. We speculate that PAI-1 protein in septic blood coursing through the
richly vascularized heart affected the PAI-1 activity assessed by zymography in this
organ.

3.4.5 Immune response during sepsis.
Increased MPO content has been reported in septic organs including the lung and liver (6,
21). Our data in Figure 3.6 (lung and liver) agree with these reports. The lack of MPO
signal in the kidney under sham conditions is consistent with the literature (15). Sepsis
reduced the MPO content in the spleen and did not change in the heart (Figure 3.6)
consistent with the trends observed by Gebska and colleagues (11). To explain the
reduced MPO content in the spleen, we speculate that the large number of neutrophils in
sham control mouse spleen (associated with the largest MPO signal, Figure 3.6) was
reduced in sepsis due to neutrophil recruitment from the blood into organs such as lung
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and liver. Ascorbate had no effect on the sepsis-induced MPO content in any organ
(Figure 3.6).
The correlation in Figure 3.7 suggests a dependence of the MPO signal on PAI-1 activity.
Previously, the level of neutrophils in blood was shown to depend on the PAI-1 protein
content (23). This dependence and the correlation shown in Figure 3.7 suggest that PAI1 may play a role in the immune response during sepsis.

3.4.6 Significance of the lack of effect of ascorbate.
We reported that delayed ascorbate bolus rapidly reverses (i.e., within 1 h) capillary
plugging in sepsis. The present data indicate that this effect is not due to ascorbate
promoting fibrinolysis of microthrombi (i.e., by ascorbate inhibiting PAI-1) in capillaries
in the skeletal muscle. The reversal of capillary plugging could be due to other
mechanisms through which ascorbate exerts its effect rapidly (e.g., ascorbate reduces
platelet aggregation and platelet-endothelial adhesion (28, 29)).
Ascorbate did not appear to affect the bacterial counts in the various organs
within 1 h post-injection. This observation is consistent with the report that short-term
ascorbate treatment failed to change the rate of superoxide production by neutrophils (7)
indicating that bacterial killing by neutrophil respiratory burst is not affected by
ascorbate. Furthermore, administration of 320 mg/kg ascorbate over 2 h did not affect
the intracellular concentration of ascorbate in leukocytes (4). We speculate that the lack
of short-term effect of ascorbate on bacterial count is of little consequence, because
bacteria in the various organs could be killed by leukocytes infiltrating these organs
during sepsis.
The lack of effects of ascorbate at 10 mg/kg in the present study does not preclude any
effects of ascorbate given at larger doses or at different time points (e.g., at the onset of
sepsis or for longer treatment periods). These effects could be subject to future
investigations.
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In conclusion, we have demonstrated that ascorbate does not affect bacterial
content, PAI-1 or MPO in organs with high immune activity. These results suggest that
the beneficial effect of ascorbate on capillary bed perfusion is not accompanied by effects
of ascorbate on the fibrinolytic or immune responses in septic organs.
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Chapter 4
Effect of ascorbate on plasminogen activator inhibitor 1
expression and release from platelets and endothelial cells
in an in-vitro model of sepsis

A version of this chapter has been submitted to Microcirculation.
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4.1 INTRODUCTION
Sepsis, a systemic inflammatory response to an infection, leads to numerous
physiological abnormalities, including a fibrinolytic abnormality due to elevated plasma
levels of the PAI-1 (11, 12, 24). The fibrinolytic abnormality could be critical at the
microcirculatory level because elevated PAI-1 levels could inhibit the plasmin-mediated
dissolving of microthrombi and thus contribute to DIC. To this end, we have shown that
sepsis causes plugging of the capillary bed, involving increased occurrence of both fibrin
plaques and platelet adhesion/aggregation in capillaries (22, 28, 29). To our knowledge,
the role of the fibrinolytic abnormality in sepsis-induced capillary plugging is not known.
We have reported that, in septic mice, an intravenous injection of ascorbate delayed 6 h
after the onset of sepsis unplugs capillaries. Although numerous mechanisms could
explain this beneficial effect of ascorbate (22), it is possible that ascorbate enhances the
dissolving of capillary microthrombi by inhibiting PAI-1, to account for the observed
unplugging of capillaries. Oxidative stress has been implicated in the increase in both
mRNA and protein expression of PAI-1 in endothelial cells (8).
Because endothelial cells and platelets (i.e., cells in the milieu of capillary microthrombi)
can release PAI-1into the extracellular space (2, 16, 21), the objective of the present
study was to use a simple in vitro and ex vivo models of sepsis to examine whether
ascorbate affects PAI-1 expression and release from these two cell types. We
hypothesized here that ascorbate reduces the expression and release of PAI-1 in
endothelial cells or platelets in sepsis. Because the beneficial effect of ascorbate against
capillary plugging has been shown to depend on eNOS-derived NO (22), we also
hypothesized that the PAI-1 release is NO-dependent.
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4.2 METHODS
4.2.1 Animal preparation
All experiments were conducted under protocols approved by the University of Western
Ontario Council on Animal Care. Endothelial cells for in vitro experiments were
obtained from male wild type C57BL/6 mice (age: 1.5 – 3 months) from Charles River
Laboratories (Sherbrooke, Quebec, Canada). Preliminary experiments indicated no
gender specific differences in platelet function, therefore platelets for ex vivo experiments
were obtained from male or female wild type mice of the same strain. Mice were
anesthetized with ketamine (80 mg/kg) and xylazine (4 mg/kg) prior to cell harvest or
platelet collection. All supplies were purchased from Sigma Aldrich (Oakville, ON,
Canada) unless otherwise stated.

4.2.2 In-vitro model of sepsis in cultured endothelial cells
Endothelial cells were harvested from the whole hind limb skeletal muscle as previously
described (1, 15). We have chosen this tissue because sepsis-induced capillary plugging
and the beneficial effect of ascorbate against this plugging has been observed in the
mouse skeletal muscle (22, 26). The muscle was excised, cut into 2 mm diameter pieces
and digested in 25 mls of digestion solution containing 21 mg collagenase, 3 mg dispase,
3 mg trypsin and 41 mg bovine serum albumin for 30 minutes. The digest was strained
through nylon mesh, centrifuged at 805 rcf for 5 minutes, then the pellet was resuspended
in culture medium containing 20% fetal bovine serum, heparin (5 U/ml), endothelial
growth supplement (100 µl/ml), antibiotic-antimycotic solution (10µl/ml) and Lglutamine (0.1 µg/ml) in DMEM/F12 HAM. The endothelial cells were grown to
confluence and then were purified using a GS-I lectin coated magnetic bead
immunoseparation. This method has been demonstrated to yield nearly 100% pure
endothelial cells as assessed by vWF (1). We randomly chose cell lines to test for vWF
to confirm continued specificity of this method. The cells were cultured and used for
experiments up to passage 10. For each experiment, cells were grown to confluence and
treated with ascorbate (100 µM) for 1, 3, 6 or 24 hours, concurrently with either
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lipopolysaccharide (LPS) (10 µg/ml) or tumor necrosis factor alpha (TNFα) (10 ng/ml).
We used 100 µM ascorbate as it has been demonstrated to raise the intracellular
ascorbate content to approximately 5 mM, a physiologically relevant concentration in
vivo (31). The doses of LPS and TNFα were chosen as they were demonstrated to induce
platelet-endothelial cell adhesion, suggesting activation of the coagulatory pathway (32).
Alternatively, cells were treated with thrombin (0.0375 U/ml) for 3 - 5 minutes at the end
of the 24 hour period. We used LPS and TNFα as conventional agents of sepsis as these
substances have been shown to initiate endotoxemia in vivo (6, 7). The chosen dose of
ascorbate results in physiological levels of intracellular ascorbate (31). Thrombin
(0.0375 U/ml) has been used to activate platelets to mimic sepsis ex-vivo (23). We have
used this concentration of thrombin in endothelial cells as an alternative in vivo model of
sepsis (23). After completion of experiments, cell supernatants were collected and
frozen, and the cells were lysed in Tris-NaCl-Triton-EDTA (TNTE) buffer or Trizol
(Invitrogen, Burlington, ON, Canada).

4.2.3 Ex-vivo model of sepsis in isolated platelets
Blood was collected 9:1 in acid citrate dextrose solution and platelets were isolated as
detailed previously (23). Briefly, the blood was centrifuged at 179 rcf, the supernatant
was retained and centrifuged at 774 rcf to pellet the platelets. The platelet pellet was
resuspended in DPBS, divided evenly among the treatment groups and stimulated with
thrombin (0.0375 or 0.075 U/ml), LPS (10 µg/ml) or TNFα (10 ng/ml) with or without
ascorbate (100, 500 or 1000 µM). To ensure autoactivation of the platlets did not occur,
a control unstimulated platelet fraction was always included for each individual
experiment. The platelets were incubated at 37°C for 5 or 10 minutes, then centrifuged to
pellet the platelets. The supernatant was retained and frozen, and the platelet pellet
homogenized in TNTE buffer or Trizol. To determine the effect of NO on platelets, the
NO donor S-Nitroso-N-acetylpenicillamine (SNAP) (1 µM) was used in conjunction with
thrombin (0.0375 U/ml). This level of SNAP inhibits thrombin-induced aggregation of
platelets ex-vivo (23).

106

4.2.4 PAI-1 mRNA expression
mRNA was isolated using the phenol-chloroform extraction method. The isolated
mRNA was purified using DNAse I and Reverse Transcribed using Superscript II
(Invitrogen). The mRNA was quantified using Quantifast SYBR Green (Qiagen,
Mississauga, ON, Canada) as directed on a Bio-Rad CFX96 thermal cycler (Bio-Rad,
Mississauga, ON, Canada). The primers used to detect the mRNA are as follows: PAI-1
(forward: 5’-GACAGCACTGTCAGGGTCCATAG-3’ and reverse: 5’GCGGTCCTCCTTCACAAAGCTC-3’) and β-actin as a housekeeping gene (forward:
5’-TCGTGGGCCGCTCTAGGCACCA-3’and reverse: 5’GTTGGCCTTAGGGTTCAGGGGGG-3’). The mRNA was amplified using the
following cycling protocol: 95°C for 5 min and then 40 cycles of 95°C for 10 s, 60°C for
30 s and 80°C for 30 s.

4.2.5 PAI-1 protein content and release
Both intracellular PAI-1 protein (i.e., PAI-1 in cell lysates) and PAI-1 release (i.e., PAI-1
in cell supernatants) were quantified using the total PAI-1 ELISA Kit (IMPAIKT-TOT,
Innovative Research, Novi, MI) according to manufacturers directions. The ELISA can
detect PAI-1 within the 0.05 – 50 ng/ml range. Accordingly, endothelial cell samples
were diluted with TNTE buffer prior to being added to the ELISA plates.

4.2.6 Statistical analysis
Data are presented as mean ± SE. A minimum of five different cell lines were used for
the endothelial cell experiments. A minimum of four groups of pooled platelets were
used for the platelet experiments. Statistical analysis was performed using a repeated
measures one-way ANOVA and the Bonferroni multiple comparison test. Results are
significant with a P < 0.05.
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4.3 RESULTS

4.3.1 Endothelial cell PAI-1 mRNA and protein expression
mRNA analysis of endothelial cell PAI-1 expression revealed that LPS and TNFα raised
expression after 6 and 24 h of stimulation, but not after 1 and 3 h of stimulation, when
compared with control unstimulated cells (Figure 4.1). Ascorbate had no effect on the
expression of PAI-1 mRNA at 1- 6 h, but there was a tendency for increased PAI-1
mRNA in TNFα groups at 24 h. Interestingly, the LPS- or TNFα-induced increase in
mRNA seen at 6 and 24 h did not translate into increased production of PAI-1 protein at
24 h (Figure 4.2a). Surprisingly, in control cells, ascorbate increased the production of
PAI-1 protein. In LPS- or TNFα-treated cells, ascorbate had no effect on PAI-1 protein
(Figure 4.2a).

4.3.2 PAI-1 protein release from endothelial cells
For all control, LPS and TNFα groups at 24 h, the level PAI-1 protein release was greater
than the level of PAI-1 protein remaining in the cells (Figure 4.2b). Ascorbate did not
affect the PAI-1 release in any of the groups (Figure 4.2b). Figure 4.3a shows the effect
of acute stimulation of endothelial cells with thrombin. Thrombin had no effect on intraendothelial PAI-1 protein in control cells treated with either vehicle or ascorbate for 24 h
(Figure 4.3a) nor on PAI-1 protein release from these cells (Figure 4.3b).

4.3.3

PAI-1 protein release from platelets

Figure 4.4 shows that neither LPS nor TNFα affected intracellular and released PAI-1
protein levels when compared to the control unstimulated platelets. However, as
anticipated, thrombin at a concentration of 0.0375 U/ml, reduced intracellular PAI-1 and
elevated released PAI-1 protein levels from platelets (Figure 4.5). Ascorbate (100 µM)
did not affect these levels. However, ascorbate at 500 µM and 1000 µM inhibited the
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Figure 4.1. Increases in PAI-1 mRNA expression after 6 and 24 hours of endotoxin
stimulation were not altered by ascorbate. Isolated endothelial cells were stimulated
with either LPS (10 µg/ml) or TNFα (10 ng/ml) for 1, 3, 6 or 24 hours as indicated. Cells
were treated with 100 µM ascorbate (Asc) or media (Con) concurrently. Total cell
mRNA was extracted, reverse transcribed and PAI-1 mRNA was quantified using qPCR.
Neither LPS nor TNFα altered the PAI-1 mRNA expression at 1 hour (A) or 3 hours (B).
In contrast, at 6 (C) and 24 hours (D) there was a significant increase in PAI-1 expression
with both LPS and TNFα treatment. Ascorbate did not appear to have an effect on this
increase in PAI-1 expression. * P < 0.05 compared to control. n = 4 – 9 different cell
lines per treatment.
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Figure 4.2. Stimulation with LPS or TNFα did not alter the PAI-1 production or
release in endothelial cells. Endothelial cells were stimulated with LPS (10 µg/ml) or
TNFα (10 ng/ml) for 24 hours, the supernatant was collected and the cells lysed. The
PAI-1 content in the cells and released in the supernatant were quantified using an
ELISA. Ascorbate (Asc, 100 µM) treatment alone for 24 hours significantly increased
the PAI-1 production in the endothelial cells over media alone (Con). Co-treatment with
either LPS or TNFα eliminated the observed increase in PAI-1 protein. No stimulation
altered the PAI-1 release into the supernatant. * P < 0.05 compared to control. n = 4 cell
lines per group.
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Figure 4.3. Thrombin has no acute effect on the release of PAI-1 protein from
endothelial cells. Endothelial cells previously treated with ascorbate (Asc, 100 µM) or
fresh media (Con) for 24 hours were stimulated with thrombin (0.0375 U/ml) for five
minutes, then the supernatant was collected and the cells lysed. Thrombin had no effect
on the release of PAI-1 into the supernatant. Ascorbate treatment significantly increased
the PAI-1 production intracellularly. * P < 0.05 compared to control. n = 5 cell lines per
group.
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Figure 4.4. PAI-1 release by platelets is not induced by LPS or TNFα. Platelets were
isolated from whole mouse blood, stimulated with LPS (10 µg/ml) or TNFα (10 ng/ml)
for 10 minutes, then the supernatant and platelet pellets were collected and subjected to
ELISA. Neither LPS nor TNFα treatment caused release of PAI-1 from the platelets into
the supernatant. n = 6 platelet isolations per group.
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Figure 4.5. Ascorbate (Asc) does not inhibit thrombin induced PAI-1 release from
platelets. Isolated platelets were treated with ascorbate (100 µM) or DPBS, followed by
stimulation with thrombin (0.0375 U/ml) for 10 minutes, then supernatant and platelet
pellets were collected and subjected to ELISA. Thrombin induced a significant release of
PAI-1 from the platelets into the supernatant. Ascorbate had no effect on the thrombin
induced PAI-1 release. * P < 0.05 compared to control. n = 5 platelet isolations per
group.
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thrombin-induced PAI-1 release from platelets (Figure 4.6). As the pH of unbuffered
ascorbate is acidic, we tested whether this inhibition is pH-sensitive. Figure 4.7 shows
that buffered ascorbate solution (1000 µM, pH adjusted to 7.2) failed to inhibit the
thrombin-induced platelet PAI-1 release. When the pH was lowered with hydrochloric
acid to the same level as unbuffered ascorbate (pH 5.8 and 3.8), similar reductions in
platelet PAI-1 release were observed (Figure 4.8).

4.3.4 Platelet PAI-1 protein release, dependence on NO
Platelet activation by thrombin and the protective effect of ascorbate in the
microvasculature have both been reported to be NO-dependent (22, 23). Figure 4.9
shows that the thrombin-induced release of PAI-1 was independent of exogenous NO
(i.e., 5 min treatment with SNAP). Since this treatment has been shown to inhibit
thrombin-induced platelet aggregation (23), the results in this figure suggest that the
platelet PAI-1 release is independent of NO.

4.4 DISCUSSION
In the present study, we have shown that the PAI-1 production and release by the
endothelial cells and platelets in vitro/ex vivo is not affected by low dose (100 µM)
ascorbate treatment. Additionally, we have uncovered a potential pH-mediated
mechanism whereby ascorbate may be able to inhibit platelet PAI-1 release. We also
explored the NO dependence of the platelet PAI-1 release and determined that platelet
PAI-1 release may not be NO-dependent.
We have previously shown that an intravenous bolus of ascorbate can decrease
capillary plugging, resulting in improved organ function and improved survival (22, 27,
29). A persistent challenge we have faced is the complexity of the in vivo model of
sepsis and the limitations in measuring PAI-1 protein release directly into the blood by
both endothelial cells and platelets at the capillary level. The present study uses
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Figure 4.6. High dose ascorbate inhibits the thrombin induced PAI-1 release from
platelets. Platelets were treated with unbuffered ascorbate (500 and 1000 µM) or DPBS,
followed by stimulation with thrombin (0.0375 U/ml) for 10 minutes. PAI-1 in the
supernatant and platelet pellet was quantified using ELISA. Thrombin induced a
significant release of PAI-1 from the platelets into the supernatant. Both 500 and 1000
µM doses of ascorbate significantly reduced the release of PAI-1. * P < 0.05 compared
to control. # P < 0.05 compared to thrombin stimulated platelets. n = 6 platelet isolations
per group.
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Figure 4.7. pH buffered high dose ascorbate (Asc) does not inhibit the thrombin
induced platelet PAI-1 release. Isolated platelets were treated with ascorbate (1000
µM) buffered to pH 7.2 or DPBS, followed by stimulation with thrombin (0.0375 U/ml)
for 10 minutes. PAI-1 was then determined in the supernatant and platelet lysate by
ELISA. Thrombin induced a significant increase in PAI-1 release by platelets into the
supernatant. Ascorbate had no effect on the thrombin induced PAI-1 release. * P < 0.05
compared to control. n = 4 platelet isolations per group.
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Figure 4.8. Thrombin-induced platelet PAI-1 release is inhibited by low pH.
Isolated platelets were suspended in DPBS at either pH 7.4, 5.8 or 3.8, followed by
stimulation with thrombin (0.0375 U/ml) for 10 minutes. PAI-1 protein level was then
determined in the supernatant and platelet lysate by ELISA. Thrombin induced a
significant increase in PAI-1 release by platelets into the supernatant. Low pH generated
a dose-dependent inhibition of the thrombin induced PAI-1 release. * P < 0.05 compared
to control. # P < 0.05 compared to thrombin at pH 7.4. n = 3 platelet isolations per
group.
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Figure 4.9. Effect of thrombin on PAI-1 release from platelets subjected to
exogenous NO. Platelets were isolated and treated with the NO donor SNAP (1 µM) or
DPBS, and thrombin (0.0375 U/ml). SNAP did not alter the thrombin-induced platelet
PAI-1 release. * P < 0.05 compared to both control and SNAP only treatments. n = 4-5
platelet isolations per group.
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simplified in vitro and ex vivo models to examine the effect of the antioxidant ascorbate
on PAI-1 production and release in cells that would be in a very close proximity to a
developing microthrombus in vivo.

4.4.1

PAI-1 mRNA expression in endothelial cells

Our findings that endothelial cell PAI-1 mRNA is not altered after 1 or 3 h LPS/TNFα
treatment are in contrast to the PAI-1 increase reported soon after endotoxin treatment
(18). Interestingly, the increase in PAI-1 mRNA observed at 6 and 24 h mirrored that of
several previous studies (18, 19). It is possible that inter-species differences between
mouse and human cells may be responsible for the delayed response to LPS. Indeed, it
has been reported that humans have a markedly increased sensitivity to LPS compared to
mice, and that inter-species differences in sensitivity to infections can have profound
effects on survival (6, 14). Ascorbate did not appear to have any effect on PAI-1 mRNA
expression after 1- 6 h of treatment (Figure 4.1). Ascorbate tended to potentiate the
TNFα-induced increase in PAI-1 mRNA (Figure 4.1d).

4.4.2 PAI-1 protein expression and release in endothelial cells
The tendency of increased PAI-1 mRNA observed upon ascorbate treatment in control
cells translated into increased PAI-1 protein production (Figure 4.2a). Interestingly, this
increase in protein production did not lead to increased release into the extracellular
space. Additionally, treatment with LPS or TNFα largely abolished the ascorbateinduced increase in PAI-1 protein expression. It cannot be ruled out that the large
amount of PAI-1 released over 24 hours has masked an increase in PAI-1 release late in
the treatment period (i.e., if treatment increased release beginning at 23 h, 1 h of
increased release may be masked by the first 23 h of release). Consistent with these
findings, thrombin also did not initiate increased release of PAI-1 (Figure 4.3). The
findings of Figure 4.2 support the notion that endothelial cells make a significant
contribution to the total PAI-1 in the vasculature. The lack of increase in PAI-1 protein
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levels upon LPS stimulation are in contrast with previous studies in human umbilical vein
endothelial cells, where significant increases in PAI-1 were observed (18, 19). Given the
demonstrated inter-species variability, it is conceivable that the expression profile of PAI1 in mouse cells differs from that of human cells.

4.4.3 Effect of ascorbate on PAI-1 protein expression
Regarding the ascorbate-initiated increase in PAI-1 protein production, it is unclear what
mechanism is involved in this phenomenon. However, we speculate that ascorbate either
increases the stability of PAI-1 enhancing the total content, or it is acting as a stimulant to
the initiation of the non-fibrinolytic effects of PAI-1 (e.g., angiogenesis). It would be
interesting to determine what effect intravenous ascorbate might have on the vasculature
of healthy individuals.
Overall, the long time period required for ascorbate to induce any changes in the
endothelial cells (e.g., 24 h may be needed for increased PAI-1 production) argues
against ascorbate’s acute effects on fibrinolysis. Thus, in the septic microvasculature,
restoring capillary blood flow by ascorbate over 1 h period may not occur through PAI-1
inhibition. Interestingly, the increased survival during sepsis seen after ascorbate
injection suggests that increased or maintained PAI-1 production during sepsis may not
be detrimental to the outcome of sepsis. Despite studies suggesting PAI-1 is essential to
survival from sepsis, it is unclear how PAI-1 is beneficial (9).

4.4.4 PAI-1 release from platelets
Consistent with our previous findings of the lack of effect of LPS/TNFα on platelet
aggregation (23), in the present study, LPS and TNFα did not alter platelet PAI-1 release.
This finding agrees with previous work using platelets isolated from mice using both LPS
(20) and TNFα (3), though others have observed spontaneous platelet activation upon
LPS stimulation (4). It is important to note that these conflicting studies were conducted
with platelets from species other than mice, suggesting inter-species differences may be
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involved in the different responses. It is also possible that neither LPS nor TNFα directly
stimulate platelets, but rather they may stimulate the production of other signaling
molecules (i.e., thrombin) that ultimately activate platelets (10). The present ex vivo
model may lack the cells necessary for the production of these signaling molecules.
The observed PAI-1 release from platelets upon short-term stimulation with thrombin
agrees with the literature (2, 16). Ascorbate at a concentration of 100 µM did not alter
the release of PAI-1 from platelets. This is in contrast to our previous report that
ascorbate reduces the rate of thrombin-induced aggregation (23). It is possible that we
were unable to observe a reduction in the rate of PAI-1 release due to our inability to
measure PAI-1 content in real time. We observed a trend towards enhanced PAI-1
release with ascorbate treatment (Figures 4.5 and 4.7). This trend suggests that PAI-1
release may not be directly tied to platelet aggregation.

4.4.5 pH dependent effect of ascorbate on PAI-1 expression
Interestingly, treatment with 500 and 1000 µM ascorbate at an unbuffered pH
significantly inhibited platelet PAI-1 release (Figure 4.6). We observed that alteration of
pH alone yielded similar inhibition of platelet PAI-1 release (Figure 4.8). This response
was abolished when the pH of ascorbate was adjusted to 7.2 (Figure 4.7). Critically ill
patients can develop severe acidosis, where the blood pH drops below 6.8 (17), and this
level may reach as low as 6.0 in localized regions, particularly during ischemia (5).
Although this level is higher than the pH measured in the current study (pH 5.8 at 500
µM and pH 3.8 at 1000 µM), there was a trend of increasing inhibition with increasing
dose of ascorbate (Figure 4.6). It is possible that lower levels of unbuffered ascorbate
would give a physiological pH, while still inhibiting the release of PAI-1 from platelets.
Consistent with our findings of a potential pH dependence of ascorbate, it has been
reported that thrombin-induced platelet adhesion is reduced by approximately 25% at pH
7.0 and 50% at pH 6.5 (5). Our preliminary experiments with control sham mice showed
that injected ascorbate (10 mg/kg) dropped the blood pH from 7.2 to 7.0 at 5 min postinjection. Thus, our buffered ascorbate solution in the platelet experiments mimicked the
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blood’s capacity to buffer ascorbate, and indicated that the observed inhibition of
thrombin-induced PAI-1 release by ascorbate may not occur under normal physiological
conditions in vivo. Given the propensity for acidosis during sepsis, we speculate that as
the blood pH in septic mice treated with ascorbate may be lower than that in sham mice,
it is conceivable that a modest pH dependent reduction in platelet activation and PAI-1
release occurs in our septic mouse in vivo model (Chapters 2 and 3).

4.4.6 NO-dependence of PAI-1 release in platelets
Ascorbate has been demonstrated to act in an eNOS dependent manner in vivo (13, 22,
23, 25, 26). In the present study, we showed that addition of the NO donor SNAP does
not affect the thrombin-induced platelet PAI-1 release. Previously it was demonstrated
that SNAP at the same concentration reduces the rate of thrombin-induced aggregation
(23). We speculate that the PAI-1 release and the aggregation reflect the different
signaling pathways initiated by the thrombin stimulus (16, 30).
In conclusion, we have confirmed the presence and release of PAI-1 protein by
both endothelial cells and platelets, two cell types in close proximity to a developing
intravascular microthrombus. This local PAI-1 may be critical in the
development/stability of the thrombus in sepsis. Ascorbate may reduce the PAI-1 release
through a pH-dependent mechanism, thus destabilizing the thrombus and promote
restoration of blood flow through plugged capillaries. This potential mechanism warrants
further investigation.
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Chapter 5
DISCUSSION

5.1 SUMMARY

Fibrinolysis is a key component in the maintenance of the normal coagulation process,
allowing for the dissolution and removal of unneeded clots in the body. During sepsis,
capillary blood flow is reduced involving activated coagulation and microthrombi
formation in capillaries. Concurrently, fibrinolysis is impaired, stabilizing microthrombi.
However, a potential link between reduced blood flow and impaired fibrinolysis has yet
to be addressed. Ascorbate has been suggested as a potential treatment for sepsis, as it
has been demonstrated to improve capillary blood flow during sepsis. The mechanism of
the protective effect remains largely unknown. Given these effects, I hypothesized in
Chapter 2 that the capillary plugging observed in sepsis was a result of reduced
fibrinolysis, and that ascorbate is protective by increasing fibrinolysis through inhibition
of PAI-1. The results of this study are presented in Chapter 2.
As bacteria are found in the blood of septic patients, there is the potential that the
spread of bacteria among organs through systemic circulation could be reduced by the
impaired capillary blood flow and subsequent increased trapping of bacteria within the
organ(s) initially containing the most bacteria. Thus, increased PAI-1 levels during
sepsis may actually play a beneficial role by reducing bacterial spread and by promoting
the local immune response in this organ(s). For these reasons, I hypothesized in Chapter
3 that ascorbate would not alter the bacterial content, PAI-1 expression or neutrophil
recruitment in “immunogenic” organs of mice. Results supporting this hypothesis are
presented in Chapter 3.
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During sepsis, platelets become activated due to the excessive thrombin
expression along with other coagulation proteins. Platelets treated with ascorbate have
been demonstrated to have reduced activation and granule secretion. As platelet derived
PAI-1 is released through α-granule secretion, I hypothesized in Chapter 4 that ascorbate
treatment reduces the platelet PAI-1 expression in response to thrombin stimulation. The
results of this study are outlined in Chapter 4.
To support the notion that ascorbate acts in a pro-fibrinolytic manner, I showed in
Chapter 2 that streptokinase, a fibrinolytic agent, restored the capillary flow to a similar
degree to that of ascorbate. Next, to determine whether fibrinolysis was indeed altered, I
studied the mRNA expression of the plasminogen activators t-PA and u-PA, and their
inhibitor PAI-1, during sepsis. The mRNA expression of t-PA and u-PA were not altered
by ascorbate treatment. Interestingly, the mRNA expression of PAI-1 in the skeletal
muscle of septic mice was reduced by ascorbate treatment, suggesting an overall
enhancement of fibrinolysis with ascorbate treatment. Unfortunately, the increase in
PAI-1 mRNA expression did not translate into increased PAI-1 protein as measured by
western blot, ELISA or zymography. Given this discrepancy, I then determined whether
there was a difference in mRNA expression between skeletal muscle and liver.
Ascorbate did not alter the mRNA expression of u-PA or PAI-1, however t-PA
expression was dramatically reduced, suggesting a reduction in fibrinolysis. The increase
in PAI-1 expression during sepsis, and the lack of effect by ascorbate, was confirmed by
zymography. The plasmin anti-plasmin levels were severely reduced, suggesting a lack
of plasmin, likely due to an overall anti-fibrinolytic state. These results failed to support
the hypothesis that ascorbate reduces PAI-1, thereby increasing fibrinolysis.
As PAI-1 is not altered by ascorbate, I then wondered if it is beneficial to
maintain increased levels of PAI-1 in different organs of the body. First, I confirmed that
sepsis significantly increased the bacterial content in all organs, while treatment with
ascorbate reduced the bacteria in the blood only. Next, I determined that PAI-1 mRNA is
increased in all septic organs studied except the heart. Among these organs, ascorbate
reduced the mRNA expression in the skeletal muscle only. Increased PAI-1 protein
levels were confirmed in the blood plasma, lung, heart and liver by zymography, while
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ascorbate had no effect in any organ. Neutrophil content in the organs was increased in
the lung and liver, and decreased in the spleen. Ascorbate did not have any effect on
neutrophil content. These results support the hypothesis that ascorbate does not alter (i)
the bacterial content, (ii) PAI-1 expression and (iii) neutrophil infiltration in the tissues
during sepsis, suggesting that ascorbate has no effect on the immune response during
sepsis.
As it is impossible to examine individual cell types in in vivo models, I next
aimed to determine whether the endothelial cells and platelets, two cell types in direct
contact with the blood, have altered PAI-1 expression under septic conditions. I
confirmed that long-term exposure to a sepsis-like state increases PAI-1 mRNA
expression. In contrast to Chapters 2 and 3, the increase in PAI-1 mRNA did not
translate into increased PAI-1 protein expression or release by endothelial cells.
Interestingly, I determined that ascorbate alone increases PAI-1 protein expression, but
that neither endotoxins nor the coagulation activator thrombin initiated the release of this
PAI-1. Next, I showed that thrombin, but not endotoxins, induced PAI-1 release from
platelets, and that ascorbate inhibited this release through a pH dependent mechanism.
Finally, I showed that the thrombin-induced platelet PAI-1 release is independent of
nitric oxide/eNOS. These results partially support my hypothesis that ascorbate inhibits
the sepsis-induced increase in PAI-1 production/release, through the discovery of a pH
mediated mechanism. The finding that the inhibition of PAI-1 release by ascorbate is NO
independent does not support my hypothesis. These findings support the previous in vivo
studies that ascorbate does not affect PAI-1 expression/release under normal
physiological conditions.
In conclusion, the evidence presented in this thesis demonstrates that the sepsisinduced capillary plugging may be perpetuated because of an anti-fibrinolytic
environment. The beneficial effect of ascorbate on restoring capillary perfusion likely
does not involve alterations in the anti-fibrinolytic state present in the septic
microvasculature.
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5.2 GENERAL DISCUSSION

5.2.1 Comparison of the models of sepsis
The complexity of the septic process makes it a difficult disease to study. To date,
numerous mediators and cell types have been implicated in the pathology of the
inflammatory process characteristic of sepsis. A key confounding factor in studying
sepsis in humans is the presence of numerous different underlying medical conditions and
characteristics present prior to the onset of sepsis in the majority of patients (12). These
other diseases (e.g., cancer, diabetes) and factors such as age often alter the septic
condition and change the outcome (62). Despite the complexity of sepsis in the clinical
setting, animal models have been used to address the various aspects of the septic process
(15, 18, 63). The present thesis encompasses three distinct types of models of sepsis, in
vivo, in vitro, and ex vivo, to study the fibrinolytic system in the capillaries in relation to
sepsis. The relationship between sepsis and fibrinolytic factor content, bacterial load and
immune response was explored using an in vivo model. The release of PAI-1 from
endothelial cells and the mRNA levels of fibrinolytic factors in these cells were studied
using an in vitro model and the release of PAI-1 from platelets was studied using an ex
vivo model. Though all models used have limitations, they were used in conjunction to
elucidate how ascorbate improves capillary perfusion during sepsis.

5.2.1.1 In vivo models of sepsis
The endotoxemia models most often involve administration of a bolus of
lipopolysaccharide (LPS) from the Gram-negative bacteria wall, but alternative models
have used initiators such as peptidoglycan, a component of the Gram-positive bacterial
wall, and other components elevated during sepsis (15). These components initiate the
production of inflammatory cytokines including tumor necrosis factor alpha (TNFα),
interferon gamma (IFNγ) and various interleukins (51). The major advantage of the
endotoxemia model is the ease in which the experiment can be standardized (11).
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Though easily standardized, the use of the endotoxemia model has a major limitation in
its lack of clinical relevance, as endotoxins do not accurately mimic bacteria, due to the
non-replicating nature of cytokines (11), the inability of LPS to mimic Gram-positive
bacteria, (18) and the fact that LPS levels are generally low in septic humans (63).
Bacterial models are considered to be the most physiologically accurate, as the
initiation of sepsis is through a bacterial mechanism similar to that of human patients.
Direct injection of a known amount of purified bacterial culture, known as a bacteremia
model, is the most easily standardized of the three bacterial models (11). Unfortunately,
often the bacteria are killed by the immune system prior to replication; therefore the
model does not accurately mimic the septic response to an infection (9, 18). Should the
bacteria be destroyed, this model largely reverts to an endotoxemia model from the
cytokines produced initially, with the drawbacks discussed above.
The remaining two models, CLP and FIP are both based on the same principle,
namely they mimic a peritonitis model of sepsis initiated by a bowel perforation. As the
bacteria introduced are more numerous both in type and quantity, they sustain cytokine
production comparable to that seen in septic patients. Potentially the most biologically
accurate model is CLP, where the cecum is ligated to form a bowel obstruction, and is
then perforated with a needle. This method allows for a slow release of fecal matter into
the peritoneal cavity, and as a result a relatively slow onset to polymicrobial sepsis that
fairly accurately mimics that observed in human patients (11). The cytokine release is
lower and sustained over a longer period, similar to that observed in septic patients (63).
In addition, using different gauge needles, the severity of sepsis can be controlled,
allowing for the study of different degrees of perforation and different time points
depending on the length of survival for the particular perforation size. The major
disadvantages of the CLP model is the high variability in severity of sepsis depending on
surgical skill, and the potential for abscess formation around the site of puncture,
preventing the fecal matter from escaping from the cecum (15). These two factors
contribute to a high degree of variability between one animal and the next, and between
the surgical personnel. The necessity to conduct sham operations on control animals
further detracts from this model, as any surgery causes cytokine release into the blood
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stream, and surgery also has an inherent risk of introducing infection. This leads to the
possibility that some control sham animals may also develop sepsis.
The last common model of sepsis is the FIP model, where fecal matter is directly
injected into the peritoneal cavity of the mouse. Like the CLP model, the FIP model
generates a polymicrobial sepsis similar to that seen in human patients (52). The FIP
model relies less on the skill of the experimenter, as it is a simple procedure to inject
feces into the peritoneal cavity. In addition, like CLP it is possible to alter the severity by
injecting different concentrations of feces. While it is possible for sham mice to become
septic due to inadvertent bowel perforation while administering the intraperitoneal dose
of sterile saline (to accurately mimic the fluid loading and physical effects on the
peritoneum), this is less likely than in CLP as it is much less invasive. Unfortunately,
there are drawbacks to the FIP model, including the possibility of abscess formation
around the fecal injection and the possibility of injecting the feces subcutaneously instead
of into the peritoneal cavity. In addition, the sudden injection of feces is less accurate
than the CLP model at mimicking sepsis in humans, as it does not allow for a slow
cytokine release in response to a slowly increasing bacterial load (18). It is also possible
that the collection of feces from a donor animal and suspension in saline may
preferentially select for some types of bacteria over others (in particular, the anaerobic
bacteria may not flourish in an aerobic environment), as over 70 different species of
bacteria are present in a typical fecal slurry (52).
In the present studies, the FIP model of sepsis was chosen as a compromise to
balance enhanced reproducibility with a polymicrobial sepsis model, while maintaining a
model closely mimicking human sepsis.

5.2.1.2 Methodological limitations
Research using animal model of sepsis is also difficult due to the methodological
limitations inherent in these models. As a result, simplified models are constantly being
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developed to attempt to cope with these difficulties. In the present studies, I have
employed in vivo, in vitro and ex vivo models to mimic particular aspects of sepsis.
The in vivo model of sepsis is generally regarded as the most physiologically and
pathologically relevant. The various different in vivo models are detailed above (see
section 5.2.1.1). While using the FIP model of sepsis, I encountered one constant
confounding issue, the high degree of inter-individual variability between one animal and
the next. Despite using exactly the same protocol in inducing sepsis, I still observed a
7,000 fold difference in the number of bacteria in the peritoneal fluid of septic mice (see
Chapter 3). This enormous range in infection has likely contributed to the variability
observed in the other experimental parameters explored in Chapters 2 and 3. The
possibility that a protective effect of ascorbate is masked by the large variability in the
FIP model cannot be discounted. I have tried to reduce this possibility by using several
different techniques where feasible (i.e., using qPCR, ELISA and zymography to study
PAI-1). Another limitation is the inability to isolate the response from individual cell
types in the whole organ homogenate. It is entirely possible that alterations in protein
expression in the endothelial cells that line the blood vessels were masked by the proteins
present in the surrounding tissues collected in the whole tissue sampling. For this reason,
I also used an in vitro endothelial cell model.
The in vitro model employed in the present studies was a purified skeletal muscle
microvascular endothelial cell line. Using this model I was able to directly measure
mRNA and protein expression in endothelial cells alone. Although this method allows
one to zoom at the cellular level, the major drawbacks that I encountered were the
difficulty in mimicking sepsis, and the possibility of cell phenotype changing under
culturing conditions. I used cytokines known to play a role in the septic pathophysiology,
and applied them to an established in vitro model of microvascular endothelial cells. In
addition, I have obtained primary endothelial cell cultures from septic mice as a hybrid
model that includes the characteristics from the in vivo model. The hybrid model allows
examination of mRNA expression from a single cell type as in the in vitro models (see
Chapter 2). Unfortunately due to the small number of cells obtained, this model was not
conducive to the determination of protein expression.
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To study platelets, I employed an ex vivo model. The model involved removing
platelets from mice and subjecting them to various chemicals to elicit responses. As
platelets are a small component of the body, altered platelet protein expression might be
hidden by protein expressed in the tissue cells. Major drawbacks of the platelet ex vivo
model are that (i) similar to in vitro models, sepsis is difficult to model here, and (ii)
platelets by nature tend to activate and aggregate in response to being removed from the
body. Similar to the in vitro model, I used established methods of mimicking sepsis. I
also used great care to prevent platelet activation and used the appropriate controls to
determine when autoactivation occurred.
In addition to the limitations of the models, there were other methodological
issues. I noted a lack of sensitivity to detect changes in PAI-1 protein using western
blotting and ELISA. As I was able to use ELISAs to observe increases in PAI-1 protein
levels in blood plasma, it seems that the most likely source of lack of sensitivity was the
high basal levels in non-vascular cells masking a modest increase in PAI-1 in the
vasculature. Due to the inability to detect PAI-1 protein levels directly, I instead had to
rely on an alternative method using reverse fibrin zymography. The zymography
employed was modified from published methods of fibrin zymography (7, 27) with one
major alteration being the addition of exogenous u-PA. This allowed for the indirect
measurement of PAI-1 activity through the inhibition of the exogenous u-PA. As PAI-1
is reported to be responsible for virtually all of the inhibition of u-PA (45), this method
has been used as an indicator of PAI-1 activity (and indirectly PAI-1 content, see
Chapters 2 and 3). Reverse fibrin zymography on mouse blood plasma mirrored the
active PAI-1 protein detected by ELISA, validating this method. As there are two
plasminogen activators that are inhibited by PAI-1, u-PA and t-PA, it is possible that the
levels of PAI-1 are actually under-reported in the present studies due to some inhibition
of endogenous u-PA and t-PA. It is difficult to eliminate this possibility. However,
through the use of a known amount of exogenous u-PA, this method gives a measure of
the free PAI-1 (total PAI-1 minus PAI-1 reacting with endogenous t-PA and u-PA), and
therefore gives a total measure of the anti-fibrinolytic potential of the tissue. Although
the various models used had limitations and drawbacks, I have used these models in
conjunction with each other to test my hypotheses.
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5.2.2 Capillary plugging during sepsis
Sepsis causes many alterations to the vascular system, including hypotension, reduced
vascular reactivity and reduced capillary perfusion (2, 6, 56, 61). It has been reported
that sepsis can reduce capillary perfusion in the skeletal muscle to the point where less
than half of all capillaries have blood flowing through them (57). This impairment of
capillary flow has been observed in other animal models of sepsis, in their various septic
organs, and in septic patients (4, 5). The exact mechanism of this reduction in perfusion
remains elusive, with several possibilities, including a narrowing of the capillary lumen
preventing red blood cell flow, stiffening of red blood cells causing them to become
lodged in the capillary, the lodging of leukocytes in the vasculature preventing blood
flow, closing of precapillary sphincters preventing flow to certain capillaries and the
formation of microthrombi that occlude the capillaries (3, 24, 25, 34, 49). Recent
evidence lends support to the notion that microthrombi formation contributes partially to
this phenomenon, namely that fibrin was observed in the septic capillaries, and that
depletion of platelets or inhibition of the coagulation cascade partially restored capillary
perfusion (49). This partial restoration suggests that another mechanism is also involved
in the capillary plugging other than platelet adhesion and coagulation. That decreased
fibrinolysis contributes to this phenomenon is a possibility, given that PAI-1 protein
expression is increased during sepsis (33, 55). Increased PAI-1 would only serve to
further enhance the stability of the fibrin and, in conjunction with platelet adhesion,
increased PAI-1could lead to the formation of stable microthrombi that plug the
capillaries.
It has been reported that red blood cells exhibit reduced deformability during
sepsis (3). Stiffer red cells in conjunction with platelet adhesion and fibrin deposition
may serve to enhance the capillary occlusion leading to the cessation of blood flow.
Leukocytes have been observed to adhere to the endothelium during sepsis (24, 34). The
contribution leukocyte adhesion has to capillary plugging is unclear as adhesion has
almost exclusively been observed in the post-capillary venules only (49). The vascular
reactivity has also been observed to decrease during sepsis (35). The loss of vascular
reactivity serves to further derange the blood flow to the capillaries, as the arterioles
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cannot properly maintain optimal blood flow velocity through contraction and relaxation.
However, the plugging of capillaries in sepsis cannot be explained solely in terms of
closed venules or arterioles, because plugged capillaries have been observed even when
their feeding arterioles and draining venules were patent and perfused with blood (49). A
recent study observed a narrowing of the capillary lumen consistent with what might be
termed a capillary sphincter (25). It is important to note that this narrowing only
occurred sporadically in capillaries in the skin. The implication of this finding on deeper
tissue capillaries has not yet been addressed. It must be acknowledged that narrowing of
the capillary lumen could also be caused by edema of the surrounding tissue and swelling
of the endothelial cells, both common occurrences in sepsis (21, 28), however edema was
not observed 24 hours into sepsis when capillary plugging is already present (43).
Previous studies examining the capillary plugging revealed that during sepsis, many
capillaries are intermittently perfused (i.e., the red blood cells show stop-and-go
movement) (2, 57) This could be explained by the possibility that red blood cells
encounter a temporary occlusion in the capillary, completely eliminating flow, and then
re-start the flow following the release of the occlusion. The observed intermittent flow is
in direct contrast to what would be expected through closure of a precapillary sphincter,
where the occluding region would be situated immediately prior to the capillary entrance.
The present studies support the notion that during sepsis there is enhanced fibrin
stabilization due to sepsis-induced increases in PAI-1 expression. Increased PAI-1
protein levels may be beneficial to survival from sepsis. In my pilot experiments, I was
unable to identify fibrin present solely in capillaries of immunohistological sections of
the septic skeletal muscle, possibly due to the lack of appropriate antibodies for fibrin.
As a result, I could not evaluate the potential for stabilization of fibrin by PAI-1 using
immunohistology.

5.2.3 Ascorbate and capillary plugging
An intravenous bolus injection of ascorbate has been demonstrated to decrease both
mortality and capillary plugging in septic mice (49, 57, 58) Chapter 2). Ascorbate could
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accomplish this beneficial effect partially through reduced platelet activation and
aggregation in a P-selectin mediated mechanism (49, 50). As platelet depletion alone
cannot account for the reversal of capillary plugging by ascorbate, clearly another
mechanism is at play. Ascorbate has been demonstrated to act in an endothelial nitric
oxide synthase (eNOS) dependent manner (49), suggesting that it may target any proteins
that are regulated by eNOS-derived NO. As vascular smooth muscle cell tone is
regulated by eNOS/NO (10), it is possible that ascorbate-mediated increases in eNOS
activity may relax the blood vessels. Though capillaries themselves are not covered with
smooth muscle cells, it is possible that increased blood flow in the arterioles immediately
upstream from the plugged capillaries is able to restore perfusion to these capillaries.
Alternatively, relaxation of venous smooth muscle and subsequent dilation would allow
blood to properly drain from the capillaries. Ascorbate has been demonstrated to restore
the mean arterial pressure in CLP induced septic rats (58). Ascorbate also inhibits the
reduced vasoconstriction of arterioles observed in sepsis (35) and restores the arterial
response to vasoconstrictors in LPS injected humans (44). These combined arterial
alterations may improve the capillary perfusion through increased and better regulated
pressure to drive the blood through individual capillaries.

5.2.4 Fibrinolytic effects of ascorbate
Fibrinolysis is known to be depressed during sepsis, contributing to the stability of fibrin
in the vasculature. A recent study reported that t-PA mRNA is upregulated with
ascorbate treatment during sepsis (16). Several other studies have determined that t-PA is
upregulated upon ascorbate administration in other disease processes (26, 59), though
others have observed downregulation of t-PA in smokers and diabetics (42, 54). Studies
examining the effect of ascorbate on PAI-1 protein are inconclusive, with some evidence
for downregulation and other studies finding no effect (1, 26, 42, 54). The present
studies, in an attempt to clarify the discrepancies in the literature, aimed to examine the
effect of ascorbate in the context of fibrinolysis. The evidence obtained in these studies
suggests that ascorbate may not change the sepsis-altered fibrinolytic system. In
Chapters 2 and 3, the data indicate that there is no effect of ascorbate on PAI-1 on a
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system wide basis. There may be an effect on the mRNA expression of PAI-1 in skeletal
muscle, but this finding wasn't consistent with the PAI-1 protein expression. It is entirely
possible that ascorbate affects the PAI-1 expression in a delayed manner, however this
delayed effect could not explain the reperfusion in capillaries seen already 1 hour after
ascorbate injection. Data in Figure 2.3 indicate that this delayed effect is unlikely, as at 3
h post-injection (i.e., 9 h post-FIP), ascorbate had no effect on sepsis-induced PAI-1
protein increase in the blood plasma. In Chapter 4, results in vitro suggest that ascorbate
treatment for 24 hours increases the production of PAI-1 in endothelial cells.
Interestingly, co-treatment with LPS or TNFα abolished this increase. It remains unclear
what the implications of increased PAI-1 would be in a healthy individual, though it
should be noted that there is no evidence that this increased PAI-1 is released into the
extracellular space.
I showed that the platelet PAI-1 protein release is inhibited by ascorbate at low pH. It is
worth noting that in a state of acidosis, the combination of reduced platelet PAI-1 release
and unchanged PAI-1 release by endothelial cells may result in reduced PAI-1 in the
capillary blood. The observed reduction in capillary plugging in sepsis seems unlikely to
be exclusively due to a pH-mediated mechanism given the limited evidence that
ascorbate reduces blood pH (Chapter 4). Overall, these findings point to another
unknown mechanism by which ascorbate acts in a protective manner in the septic
microvasculature.

5.2.5 Potential non-fibrinolytic effects of ascorbate
Ascorbate is a well known antioxidant and it is presumable that at least some of its
beneficial effect is through a reduction of reactive oxygen species. The fact ascorbate
acts in a beneficial effect is somewhat paradoxical, as antioxidants would be expected to
diminish the respiratory burst involved in the immune response (46). Theoretically, this
could be counteracted by a bactericidal effect of ascorbate at relatively high doses (20,
68). However, in Chapter 3, I have determined that ascorbate did not alter the levels of
bacteria in any organ aside from the blood. It is important to note that the animal models
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showing a bactericidal effect of ascorbate typically use a chronic dosing of ascorbate.
This dosing could explain the apparent discrepancy between these studies and the present
one. Nevertheless, it has been demonstrated that six hours after ascorbate injection, the
peritoneal bacterial levels were unaltered (67).
Tissue factor, a major initiator of coagulation, has been demonstrated to be
activated by ROS. Succinobucol, an antioxidant, reduces this activation (31). It is
presumable that the antioxidant action of ascorbate would act in a similar manner,
reducing tissue factor, and therefore reducing the initiation of coagulation. As it is
commonly accepted that abnormal tissue factor expression is a characteristic of sepsis
(32), reduction of tissue factor would reduce coagulation and arrest the further
development of microthrombi. In conjunction with any degree of fibrinolysis (whether
rescued by ascorbate or not) a reduction in coagulation could lead to a reversal of
capillary plugging. Interestingly, depleting tissue factor improves survival during sepsis
(40), and therefore a reduction in tissue factor may be another mechanism by which
ascorbate reduces capillary plugging.
In addition to changes in the initiation in coagulation, sepsis-induced platelet
activation (i.e., P-selectin upregulation, aggregation) has been reported to be inhibited by
ascorbate administration (49, 50). This reduction in platelet activation would reduce
microthrombi formation and capillary plugging in sepsis (49).
To explain the discrepant results of the reported inhibitory effect ascorbate on platelet
activation (50) and my present study on PAI-1 release, it is possible that ascorbate only
inhibited some of the thrombin receptors. Protease activated receptors 1 and 4 (PAR1
and PAR4) are cleaved by thrombin and activate the cyclic GMP pathway. It has been
demonstrated that platelet PAI-1 release is more sensitive to PAR1 (39), while knockout
of PAR4 almost completely abolished platelet aggregation and significantly increased the
time required for P-selectin expression (60). Moreover, the use of a PAR1 antagonist did
not affect the thrombin stimulated P-selectin release (14). As PARs have been
demonstrated to play a role in eNOS derived NO production (23, 64), I speculate that
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ascorbate is preferentially altering PAR4 rather than PAR1, reducing platelet P-selectin
expression and platelet activation while maintaining normal PAI-1 release.
Another potential non-fibrinolytic effect of ascorbate is to increase red blood cell
deformability during sepsis (3). It has been demonstrated that ascorbate is present in red
blood cells, and that the levels are identical to that of the blood plasma (29). A reduction
in blood ascorbate concentration, as observed during sepsis, would presumably lead to a
reduction in red blood cell ascorbate concentration. It is unclear how rapidly the red
blood cells lose their ascorbate content. However, at 4°C, red blood cells lost nearly 25%
of their ascorbate content after 6 h of exposure to ascorbate-free medium (29). It has not
yet been determined what effect the loss of ascorbate would have on red blood cell
function. However, it is likely the loss of this antioxidant would reduce red blood cell
deformability (and thus promote capillary plugging), because treatment with the
antioxidant aminoguanidine inhibited this reduced deformability during sepsis (3).

5.2.6 Ascorbate as a treatment in septic patients
Ascorbate has been demonstrated to be safe even at very high doses. Human cancer
patients are routinely given ascorbate at doses approaching, or even exceeding, 1 g/kg
body weight with minimal side effects (65). In addition, ascorbate is inexpensive and
readily available. Given these characteristics, the only impediment to clinical trials is a
lack of understanding as to how ascorbate acts in a protective manner.
As ascorbate levels are markedly reduced during sepsis (48), supplementation
with large doses is necessary to restore the blood plasma to normal levels (19, 30, 38).
There is no evidence of a detrimental effect of ascorbate at high levels in non-cancer
patients (16, 36, 37), therefore given the demonstrated safety of ascorbate, this is not an
impediment to its development as a therapy for the treatment of sepsis.
The use of ascorbate administered with vitamin E reduced mortality and multiple organ
failure in both septic and non-septic critically ill patients (8, 38). Very recently, the use
of ascorbate alone on a small number of severely septic patients (Phase I trial) has been
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shown to have beneficial effects on various markers inflammation, the length of hospital
stay, and 28-day mortality (17).
A randomized controlled study of critically ill patients concluded that administration of
glutamine and vitamins including ascorbate did not improve the mortality after 28 days
(22). It is important to note that this study involved enteral administration of ascorbate
along with four other vitamins and minerals, rather than a single intravenous bolus of
ascorbate as it has been used in the present thesis. It is conceivable that the reduction in
capillary plugging observed could reduce survival in the longer term (i.e., after 28 days).
Survival studies in mice show that ascorbate injection at the onset of sepsis, or delayed to
6 h of sepsis, significantly decreased mortality (57, 67). I have demonstrated in Chapter
4 that, after ascorbate administration, the bacterial content in the organs is not altered,
indicating that ascorbate does not promote the spread of infection, even though increased
capillary flow could theoretically reduce bacterial trapping in the organs.
The efficacy of ascorbate as a treatment may be enhanced due to its high
bioavailability and ability to accumulate in endothelial cells when given intravenously
(66). Ascorbate is rapidly taken up by endothelial cells through vitamin C transporters
and accumulates to a steady state concentration of approximately 16 mM (66). Its safety
and efficacy is further enhanced by the fact that excess circulating ascorbate is rapidly
excreted from the body by the kidneys (13). This protects endothelial cells through the
antioxidant capacity of the ascorbate, while allowing for the normal production of ROS in
cells involved in the respiratory burst, and preserving the bactericidal role of ROS in the
immune system (46).
Despite the relative safety of ascorbate, high doses can result in discomfort due to
a number of side effects. Frequently, patients have gastrointestinal disturbances such as
nausea, diarrhea and pyrosis and increased urination accompanied by a burning sensation
(47). It can also result in red blood cell hemolysis and vitamin B12 deficiency (47). In
addition, acidification of the urine over a longer time period (months to years) increases
the risk of kidney stones (53). The efficacy of certain drugs can be altered by high dose
ascorbate, and some pathological conditions, particularly relating to excess transition
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metal concentration in the blood (including excess iron due to hemocromatosis,
sideroblastic anemia and thalassemia) can lead to a prooxidant state (47). These
conditions are relatively rare, but caution would be necessary when using ascorbate as a
treatment in these patients.

5.3 Summary, future directions, and overall findings of this
research
Overall, the present studies show that sepsis alters the fibrinolytic system, primarily
through an increase in PAI-1, and that ascorbate does not appear to alter this increase. In
Chapter 2, I showed that ascorbate does not alter the sepsis-induced increase in PAI-1
protein in the skeletal muscle or liver. Ascorbate did partially restore towards control the
low platelet count in sepsis. However, there was no effect on any measurements of the
coagulability or fibrinolytic potential of the blood. In Chapter 3, I extended my study to
confirm that ascorbate did not alter the PAI-1 expression in a variety of different organs,
confirmed that ascorbate had no effect on the bacterial levels in tissues aside from the
blood, and determined that there is no effect of ascorbate on neutrophil recruitment to the
infected organs. Chapter 4 included an exploration of the effect of ascorbate on PAI-1
expression and release by platelets and endothelial cells. I determined that ascorbate may
inhibit PAI-1 release by platelets at high concentrations, while ascorbate increased
production of PAI-1 in endothelial cells. The effect of ascorbate on platelets was
observed to be pH sensitive; however the implications of this finding are unclear, as it is
uncertain whether the blood pH would be low enough after ascorbate injection to induce
this effect. I demonstrated that PAI-1 mRNA was inhibited by ascorbate in the skeletal
muscle in Chapter 2. I have shown that although endothelial cells release PAI-1 protein,
the overall contribution to the total blood plasma PAI-1 level might be low (Chapter 2).
Overall, the evidence presented points to a lack of effect of ascorbate on sepsis induced
PAI-1 expression, suggesting other mechanisms are responsible for the beneficial effects
of ascorbate seen in the microcirculation.
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Several questions remain unanswered about the effect ascorbate might have on
the fibrinolytic system. In Chapter 4, I found that low pH inhibits platelet PAI-1 release.
This finding is intriguing, as unbuffered ascorbate will have some effect on the blood pH,
particularly near the site of injection. Future studies should explore this further,
determining the degree of effect ascorbate has on blood pH, the length of time and
threshold pH in order to inhibit platelet PAI-1 release, and how long this phenomenon
lasts after the pH increases. As severely septic patients have been known to have severe
acidosis with a blood pH below 6.8 (41), the possibility that low blood pH in conjunction
with ascorbate might reduce platelet activation and PAI-1 release is intriguing and
warrants future study. As a blood pH below 6.8 generally leads to a poor prognosis, it
should be investigated whether ascorbate can reduce platelet activation in a slightly acidic
environment between 6.8 and 7.0. An important question to be answered is whether
human patients can be effectively administered ascorbate in a buffer at pH 7.2 or whether
it must be unbuffered to be effective.
Another question to be explored is the implication of ascorbate increasing PAI-1 protein
expression in endothelial cells. It is unclear whether ascorbate is increasing the
production of PAI-1 or stabilizing the existing PAI-1. It is also unclear why the PAI-1
expression would increase after ascorbate treatment, and whether long-term treatment
with ascorbate would boost PAI-1 protein expression in healthy individuals. Future
studies should explore the possibility that PAI-1 protein is increased in healthy humans
upon ascorbate treatment. If PAI-1 is indeed increased, it would be necessary to
determine how this could be beneficial, as this effect would appear to be detrimental at
first glance. In addition to the above studies, it is important to continue work with the
septic model to determine what other pathways ascorbate may affect. It has yet to be
determined whether ascorbate affects red blood cell deformability, as this is another
potential mechanism to explain the protective effect in capillaries. Importantly, ascorbate
level in red blood cells reflects that of the blood plasma (29). To the best of my
knowledge, it has not been determined whether the sepsis-induced decreases in blood
plasma ascorbate levels are reflected in the red blood cells.
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